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Bladder cancer (BC) is the fourth commonest male malignancy 
worldwide and one of the most expensive to manage. The two greatest 
risk factors are tobacco smoking and occupational carcinogen exposure. 
In chapters 3 and 4, I contemporize the landscape of two leading 
causes for BC via a systematic review and meta-analysis of the 
published literature. I find that current smokers (versus ex-smokers or 
non-smokers) and those in tobacco, dye and factory industries have the 
greatest BC incidence.  
Carcinogenesis is the result of many molecular interactions and 
pathways that are not completely understood. Changes to RNA 
processing and transport are known to play a role in cancer biology. 
Transport of mRNA from the nucleus to the cytoplasm is essential for 
eukaryotic gene expression. ALYREF is central to the major mRNA 
export pathway involving the TREX complex; however, it is frequently 
down-regulated in high grade tumours. In chapter 5, we show that a 
previously uncharacterized cancer testis antigen LUZP4 defines a novel 
mRNA export pathway up-regulated in cancer.  
Post-translational modifications provide another level of gene 
expression control. In chapter 6, we show that poly (ADP-ribosyl)ation 
results in a global mRNA export block and alters TREX assembly by 
modifying the interaction between ALYREF and the RNA helicase 
UAP56 upon DNA damage. We show for the first time that PAR can 
bind UAP56 and identify the specific binding site.  By advancing our 
	 18	
knowledge of the LUZP4 mRNA export pathway and the effects of poly 
(ADP-ribosyl)ation on mRNA export we identify possible future targets 
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Chapter 1: Introduction 
 
In this chapter I will introduce the background work and concepts that 
informed my hypotheses. In particular, attention is given to the biology 
of cancer, the advents of novel cancer detection mechanisms and the 
details involved in mRNA export and its potential links to cancer.  
 
1.1 THE UROLOGIST AND CANCER 
 
Cancer is the creation of abnormal cells that grow beyond their usual 
boundaries (World Health Organisatiion (WHO), 2015). In the UK there 
are 331,487 incident cases of cancer and 161,823 deaths per year. The 
10-year survival rate for all cancers combined was 50% as of 2011 
(Cancer Research UK, 2014). Whilst we understand a lot about 
carcinogenesis there is still much room for improvement. It is clear that 
cancer has a molecular basis. In other words, all cancers result from 
molecular alterations in the cell’s machinery, which occur as changes in 
genetic content or epigenetic expression of cellular proteins. These 
alterations create abnormal cells, which may then develop into 
malignant tissues that may metastasize leading to morbidity and death.  
 
Hanahan and Weinberg (2000 and 2011) in a landmark review 
proposed 6 hallmarks of cancer in detail; 1) resisting cell death, 2) 
sustaining proliferative signaling, 3) evading growth suppressors, 4) 
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activating invasion and metastasis, 5) enabling replicative immortality 
and 6) inducing angiogenesis (Hanahan and Weinberg, 2000) (Figure 
1,1). DNA repair was subsequently included (Hanahan and Weinberg, 
2011). Whilst, these hallmarks are shared amongst all cancers, there 
are differences in how (and to what extent) each cancer implements 
these phenotypes and so clinical oncologists worldwide now accept the 
view that each cancer may be personalized at the genetic and molecular 
level. This is true for the aetiology, natural history and also for the 
potential molecular targets for diagnostics and treatment.   
 
As an Urologist, my interests lie predominantly in bladder cancer (BC). 
BC mostly arises from the urothelial lining (see Figure 1.2a.) of the 
urinary tract. These tumorous are termed urothelial cell carcinoma 
(UCC), although historically the term transitional cell carcinoma (1973 
WHO definition) was used. Around 10% BC are not UCC, and include 
















Figure 1.1. The hallmarks of cancer. Adapted from Hanahan D and 









1.2 BLADDER CANCER 
BC is the 4th most common malignancy in males worldwide (Chavan et 
al., 2014; van Rhijn et al., 2009). In 2008 there were an estimated 
382,700 new cases of BC worldwide, with 150,300 resultant deaths 
(Chavan et al., 2014). Tobacco smoking and exposure to occupational 
carcinogens are the two most common aetiological risk factors (Burger 
et al, 2013). Most tumors arise following exposure to exogenous 
carcinogens that enter the circulation through inhalation, ingestion or 
skin contact. 
 
The urinary bladder is made of numerous layers, from a urothelial 
luminal surface layer through to muscle and peri-vesical fat tissue (see 
Figure 1.2a). BC is commonly stratified into non-muscle invasive 
(NMIBC) and muscle-invasive (MIBC). NMIBC depicts cancers which 
are confined to the lamina propria and do not invade beyond into the 
muscle layers of the urinary bladder. Prognostic profiles and treatment 
approaches vary between these two categories of disease, with MIBC 
having a far worse prognosis and requiring more aggressive clinical and 
surgical management, which confers a high morbidity burden. In the UK, 
the overall survival rate from BC is 50 % at 10 years. However, this 
ranges from 90 % to 10 % from disease stage 1 to 4 (see Figures 1.2a. 
and b.) (Cancer research UK, 2015). 
BC is also an expensive disease. In the USA, BC represents >3 % of all 
cancer-related spending, with the average cost associated with a 
diagnosis of muscle-invasive bladder cancer set at approximately 
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$150,000 per patient (Svatek et al., 2014). For early stage (NMIBC) 
cancers, the cost per capita was approximately $8,000 as of 2002, but 
this was noted to be widely variable depending upon the management 
strategies of the host centre (e.g. intensity of cystoscopic surveillance – 
the gold standard). One review has suggested that BC has the greatest 
cost per cancer patient (van Rhijn et al., 2009). 
 
BC has a latency period from carcinogenic insult to presentation of 
disease of approximately 20 years (Cohen et al., 2000). It is suggested 
that following a carcinogenic exposure the transcriptional programme of 
the urothelium undergoes a malignant transformation, with alterations in 
several genes (e.g.TP53) (Cheng et al., 2010). This effect may be 
dependent on somatic mutations or on epigenetic changes. Another way 
of describing this phenomenon is ‘field cancerization’, where there is a 
pre-neoplastic shift in fields of cells leading to cancerous phenotypes 
(Gabriel et al., 2012). Gravity is given to this hypothesis by the multi-
focality frequently displayed by BC. Catto et al (2006) showed that 90% 
of multifocal tumours arise from the same clone (Catto et al., 2006). 
Certainly it does seem that there is both reversible and permanent DNA 
damage that contributes to BC onset. This is supported by the 
observation that tobacco smokers that quit still have an increased 
incidence compared to never-smokers but a decreased risk compared 




1.3. NEED FOR A NEW BIOMARKER FOR BLADDER 
CANCER 
BC survival has not improved in more than 30 years (Lotan et al., 2014). 
Potential areas in which improved survival may occur are 1). novel 
therapies and 2). improved early detection mechanisms. There have 
been few therapeutic breakthroughs, with the recent exception of PDL-1 
inhibitors (Powles et al., 2014), and so better diagnostic or prognostic 
biomarkers seem a more realistic opportunity. Biomarkers can be 
diagnostic (is there disease or not?) or prognostic (what is the likely 
outcome of this disease going to be?). There is no accepted serum 
marker for BC. The presence of haematuria (blood in the urine) is the 
current best marker of disease, but this can be caused by a number of 
pathologies including infection and kidney stones. The ideal biomarker 
should be detectable/interpretable at an early stage of disease prior to 
unsalvageable changes; it should be sensitive enough to correlate with 
disease severity; the mode of extraction should be non-invasive and 
acceptable to patients and the mechanism of action should be known 
(National Academies, 2008). The key principle is detecting BC before it 
becomes invasive (MIBC). The rate of cancer specific survival is more 
than 90% in patients with NMIBC, but this reduces to less than 50% in 
invasive disease (Lotan et al., 2014; Cancer research UK, 2015). At 
diagnosis, roughly one-quarter of BCs are invasive. Currently, there is 
no screening programme for BC in the UK (unlike breast and cervical 
cancers (Breast cancer screening, www.nhs.uk; cervical screening, 
www.gov.uk). The merits of a BC screening programme have been 
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extensively tested using haematuria as a surrogate marker of disease. 
Messing et al (2006) studied the use of home urine dipstick measuring 
of non-visible haematuria in a group of 258 patients in the US. They 
found that screening men aged 50+ resulted in detecting tumours earlier 
and reduced overall mortality. Britton et al (1989 and 1992) and Whelan 
et al (1993) found similar results. The criticisms/limitations of these 
studies are that all study patients were at least 50 years old, diagnosis 
of BC relies on further invasive testing and there are non-cancer causes 
of haematuria resulting in false-positives for BC. However, these studies 
showed that haematuria is a precursor to BC and early detection will 
confer benefit to patient outcomes. 
In the UK, patients with haematuria are referred to clinic on a ‘2-week 
wait’ emergency referral pathway due to the persistence of microscopic 
(non-visible (NVH), which is blood in the urine detected on a dip-stick 
test) or macroscopic (visible haematuria (VH). 2-5% of patients with 
NVH, will have cancer (Lotan et al., 2014) and therefore many patients 
referred to clinic will be disease-negative (hence there are a lot of 
unnecessary investigations) but the risk of cancer increases to around 
40% in patients with VH. 
 
The current gold-standard investigation for the patient suspected of 
having BC is the flexible cystoscopy. This involves roughly a 30-minute 
hospital slot. During this appointment, the patient is first dressed 
appropriately into a gown by an attending nurse. The patient is then 
asked to provide a urine sample to rule out current infections. Next, the 
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surgeon will consent the patient for the procedure and following this 
explanation will perform it under a local anaesthetic. The patient is then 
given a description of the findings and discharged from clinic after re-
dressing. If the findings at flexible cystoscopy are suspicious, then to 
clinch the diagnosis of BC, the patient will usually have a formal, rigid 
cystoscopy under a general anaesthetic. At which point the area of 
suspicion will be biopsied or more convincing tumours will be resected 
and the patient may or may not be given intra-vesical (intra-bladder) 
chemotherapy. 
 
There is a consensus that cystoscopy is time-consuming, invasive and 
expensive and hence any breakthrough that can obviate the need for 
this procedure entirely or make selection of patients for cystoscopy 
more narrowed-down would be well received. 
 
1.4. CURRENT BEST ATTEMPTS AT FINDING A 
BIOMARKER FOR BLADDER CANCER 
NMP-22: The presence of this urinary nuclear matrix protein (NMP) in 
the urine of BC patients has been known since the 1990’s (Soloway et 
al., 1996). During the life cycle of the bladder urothelial surface, the old, 
dead, luminal surface is shed into the passing urine. NMP is found in 
bladder urothelium, therefore when this layer is shed it is found in the 
excreted urine. The relevance to BC of NMP is that it reflects the mitotic 
activity of cells test (Lotan et al., 2014). The NMP22 bladdercheck® 
detection test is an FDA approved point-of-care test (Lotan et al., 2014) 
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based on an ELISA kit using an antibody to NMP22.  The assay is 
performed by adding 4 drops of voided urine onto the device; this can 
be read approximately 40 minutes later (Lotan et al., 2014). The 
average kit can detect NMP22 at a sensitivity of up to 0.06ng/ml 
(Mybiosource.com, 2016). In a study by Stampfer et al (1998), NMP22 
was compared with urinary cytology as a means of BC detection. The 
sensitivity and specificity of NMP22 was 68% and 80% respectively, 
compared to a sensitivity of urinary cytology of 31-40% (Stampfer et al., 
1998). Other studies have also found NMP-22 to share favorable 
predictive rates when couple with urine cytology (Soloway et al., 1996). 
However, NMP22 has failed to provide more reliable diagnostic 
evidence than cystoscopy (Friedrich et al., 2003). Grossman et al (2006) 
found in a prospective cohort study of 103 US patients that NMP22 
correctly identified 90% of BC (Grossman et al., 2006). The test was 
99% accurate with concurrent cystoscopy. Grossman et al (2006) 
concluded that because neither cystoscopy nor NMP22 were 100% 
sensitive, that combination investigation was best practice. 
Subsequently, NMP22 is used more widely in the US but is not in the 
UK. Sensitivity rates have been a persistent rate-limiting step in the 
pursuit of a BC biomarker. One future approach may be to use such 
markers as adjuncts in clinic to help stratify patients as low- versus high-
risk, so that cystoscopy can be more focused. Similar stumbling blocks 
have been found with UroVision, Immunocyst and the Bladder Tumour 
Antigen testing (BTA stat). 
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ImmunoCyt: An immunocytological test that uses fluorescence-labelled 
antibodies to 3 commonly exfoliated antigens in urothelial cancer cells 
(Greene et al., 2006). One antibody is directed against a high-molecular 
weight form of glycosylated carcinoembryonic antigen (CEA) and the 
other two are against mucins (Reinhert, 2012; Greene et al., 2006). 
Mucins are normally occurring high-molecular weight proteins found on 
epithelial layers. In malignant cells, the mucins are of lower 
glycosylation, which exposes their protein backbone making them more 
accessible to the antibodies (Greene et al., 2006) and as such are 
detected in greater number. The test is positive when at least one cell of 
either a green or red fluorescence is seen (Reinhert et al., 2012). The 
test is better at detecting MIBC than NMIBC (Reinhert et al., 2012). 
Limitations are that at least 500 cells without a fluorescent signal must 
be present for the sample to be called negative. Furthermore, there are 
issues with background signal (noise) that can cause inter-user 
error/bias (Greene et al., 2006). 
 
UroVysion: This kit is designed to detect aneuploidy for chromosomes 
3, 7, 17, and the loss of 9p21 locus (tumour suppressor). It uses FISH 
(fluorescence in situ hybridization) technology to detect these 
abnormalities in patient urine (Abbotmolecular.com, 2016). A DNA 
probe is used to identify the aneuploidy (Reinhert et al., 2012). A 
positive result is achieved if the correct ratio is seen between number of 
cells and abnormal chromosomes. Limitations of the system are: a 
reduced reading accuracy if there are excessive amounts of 
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granulocytes or bacteria in the sample and that it is also dependent on 
the user having normal colour vision to read the detection device. Lastly, 
tumours less than 5mm are not detectable (Abbotmolecular.com, 2016).
  
  
BTAstat®: This test relies on an agglutination reaction for basement 
membrane complexes (Murphy et al., 1997). The technology was 
generated after analysis of BC patient urine (confirmed on biopsy) was 
conducted for common antigens (Kinders et al., 1998). The BTAstat® 
test uses monoclonal antibodies directed towards human complement 
factor H related protein (hCFHrp) and human complement factor H 
(hCFH). These proteins serve to block the alternative complement 
cascade at sites of cancer cell growth, thus preventing the normal cell 
lysis of ‘foreign’ cells as detected by the host immune system. BTAstat® 
uses a FISH based technique (BTAstat®Test, btastat.com). The 
benefits of this test, alongside NMP-22 are that they are ‘point of care 
tests’, whereas others require trained technicians (Dey, 2004). 
Limitations include the unknown effects of some benign diseases on the 
test results.  
 
Emerging fields: As we understand the molecular profile of cancer we 
have learned that each cancer uses different ways to achieve the 
necessary common hallmarks. As the unfolding of each cancer can 
happen in different ways, with genetic alterations being somewhat 
personalized.  In more recent years, researches have focused more and 
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more on the aberrant expression of non-coding RNAs such as micro 
RNAs, epi-transcriptomic events such as DNA methylation and the 
ectopic expression of cancer testis antigens (CTAs). For the purpose of 
this PhD, I focus predominantly on the role of CTAs and post-



















Figure 1.2a. A diagram depicting the different pathological stages of BC 
(Based upon the TNM staging of bladder cancer)     
    
T-stage Description 
Tx Tumour unable to be assessed due to lack of information/tissue 
T0 No tumour evidenced from histology 
TiS Carcinoma in-situ: A flat tumour  
Ta Non-invasive papillary carcinoma 
T1 Tumour invades subepithelial connective tissue 
T2a and T2b T2a invades superficial muscle. T2b invades deep muscle 
T3a and T3b T3a microscopically invades perivesical tissue. T3b invades macroscopically 
T4a and T4b T4a invades prostate, uterus or vagina. T4b invades pelvic or abdominal wall 
 
Figure 1.2b. Staging of urinary bladder cancer. Adapted from Babjuk M 
et al. (2015). Guidlelines on non-muscle-invasive bladder cancer (Ta, T1 
and CIS). European Association of Urology.  
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1.5. CURRENT TREATMENT OF BLADDER CANCER 
NMIBC is typically treated with a transurethral resection of the tumour 
(TURT) with the stratified use of adjunctive intravesical chemotherapy. 
TURTs are performed under a general anaesthetic and involve 
cystoscopic inspection and thermal coagulation or resection of tumours. 
Adjuvant chemotherapy usually comes in the form of Mitomycin C. This 
is an alkylating agent that ultimately results in DNA cross–linking and 
inhibition of cell growth. It is normally administered immediately 
following the TURT and must remain in the bladder for 1 hour. 
Alternative regimes include the use of Bacille Calmette Guerin (BCG), 
which is an attenuated form of mycobacterium bovis. This is normally 
administered as a 6-week course of intravesical instillations.  
MIBC requires radical treatment if cure is to be obtained. This may be 
with radical surgery (cystectomy) or radiotherapy (with/without radio 
sensitizers or systemic chemotherapy). Radical cystectomy in males 
includes the prostate and seminal vesicles, and in females usually 
includes removal of all the organs within the anterior pelvic compartment 
(pelvic exenteration). If the disease is metastatic or is non-organ 
confined then survival may be improved with chemotherapy. Regimes 
may include in Cisplatin, Carboplatin, Gemcitabine, monoclonal 
antibodies, or Docetaxel among others (Babjuk et al., 2015; Witjes et al., 
2015). A randomized controlled trial by Sternberg et al (2015) involving 
284 patients evaluated the difference in overall survival between those 
given immediate versus deferred chemotherapy. Four different 
combination chemotherapy regimes were used including gemcitabine, 
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cisplatin, methotrexate, vinblastine and doxorubicin.  There were no 
statistically significant differences between administering chemotherapy 
within 90 days of cystectomy or at the first relapse (Sternberg et al., 
2015). The concluding remarks suggested that further analysis is 
required to assess subgroup patient populations who may benefit from 
specific treatment regimes at more defined time-points 
There is a drive in oncology to engineer tailored diagnostic and 
treatment avenues. To achieve this, we must understand the molecular 
basis of carcinogenesis. 
 
 
1.6. EXPORT OF NASCENT mRNA AND RNA 
PROCESSING EVENTS 
Central to molecular biology is the concept, in eukaryotic cells, that DNA 
must be transcribed into messenger RNA (mRNA) and then delivered 
through the nuclear pore to the cytoplasm where it can be translated 
into a protein. This is the pathway of gene expression. When a particular 
mRNA transcript is nascently synthesized, there is no guarantee that is 
will create a functional protein. To become an active protein, pre-mRNA 
must be processed and licensed into mRNA (Kelly and Corbett, 2009). 
mRNA export involves a process of  co- and post-transcriptional quality 
control applied to these nascent RNA transcripts generated by RNA 
polymerase 2 from DNA (Moore and Proudfoot, 2009). These include 
splicing (removal of introns and eventual formation of exon-junction 
complexes at sites of exon fusion), 5’capping (with a 7-methylguanosine 
	 37	
cap that protects nascent transcripts from degradation) and 
polyadenylation (the placement of multiple adenosine residues at the 3’ 
end of the transcript by poly(A) polymerase) followed by chaperoning 
these transcripts in the form of a messenger ribonucleic particle (mRNP) 
to the nuclear pore receptor NXF1 (Moore and Proudfoot, 2009; Hung et 
al., 2010; Viphakone et al., 2012). In eukaryotes, there is a nuclear pore 
that must be negotiated (Rabut et al., 2004). Macromolecular ‘cargo’ is 
exported via nuclear pore complexes made up from aqueous channels 
known as nucleoporins (Cronshaw et al., 2002; Rout et al., 2000). Such 
transcripts are eventually permitted into the cytoplasm for translation 
into proteins and eventually degraded by the RNA decay machinery 
(Moore and Proudfoot, 2009). Post-transcriptional regulation provides a 
further level of control, whether this is for homeostatic or quality 
assurance purposes. Levels of transcripts with quick turnovers and short 
half-lives can be more tightly regulated, and mRNAs within similar 
functional groups share similar decay characteristics (Yang et al., 2003). 
Decay can occur via deadenylation, decapping (both of which permit 
access of exonucleases to the mRNA). Alternatively, the exosome may 
be recruited to mRNAs via surveillance mechanisms including 
nonsense-mediated decay and non-stop decay (where premature stop-
codons are erroneously incorporated during splicing (Mitchell and 
Tollervey, 2003; Wu and Brewer, 2012). 
Transcription of pre-mRNA by Pol II: RNA polymerase II (Pol II) has a 
globular structure with an enlarged central active site wherein the 
double stranded DNA template to be transcribed is forced apart into two 
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strands (Moore and Proudfoot, 2009) (Figure 1.3). This site permits 
nucleotide access (to build the complementary RNA from the single 
stranded DNA template strand) and RNA exit (Moore and Proudfoot, 
2009). Next to this exit channel lies the CTD (carboxyl terminal domain) 
of the large subunit of Pol II. Reversible phosphorylation occurring at 
different sites in this domain directs the elongation fate of the transcript 
(Moore and Proudfoot, 2009).  Transcriptional termination requires a 
poly(A) signal (see later) and termination is triggered by the recognition 
of this signal and subsequent pre-mRNA cleavage. Cleavage of nascent 
transcripts at this stage is necessary to optimize mRNA processing 
downs-stream (West and Proudfoot, 2009).  
  
5’Capping: This is the first RNA processing event. Pol II transcripts, 
such as mRNA are marked by an N7-methylated guanine (m7G) cap 
that is co-transcriptionally tethered to the 5’end of the RNA. This serves 
as a signal for appropriate engagement of proteins required for 
downstream processing such as splicing (Gebhardt et al., 2015; 
Izauralde et al., 1994). The ‘cap’ is bound to the RNA by the nuclear 
cap-binding complex (CBC). This complex has a heterodimer 
arrangement formed by CBP20 and CBP80 (Izauralde et al., 1995). 
CBP20 directly associates with the cap and CBP80 (its adaptor) 
stabilises this interaction (Gebhardt et al., 2015). The ability of CBP80 to 
bind ALYREF, a component of the canonical Transcription Export 
Complex (TREX), provides evidence that this process is related to 
mRNA export. Finally, the cap protects the mRNA from 5’-3’ 
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exonuclease activity (Shatkin and Manley, 2000). 
 
Splicing: Splicing is the removal of non-coding introns from the nascent 
pre-mRNA. There is a consensus view that the majority of splicing 
occurs co-transcriptionally. The spliceosome is recruited to actively 
transcribing genes, and this assembly is coordinated by small nuclear 
RNA proteins (snRNPs) (Moore and Proudfoot, 2009).  The U1 snRNP 
is the first to associate to the newly formed 5’ splice site in the first intron 
of the transcript followed by U2 and U5 snRNPs when the remainder of 
the first intron is synthesized (Moore and Proudfoot, 2009). The 
spliceosome then forms. The exons are joined together to form the RNA 
coding sequence and an exon-junction complex is deposited at sites of 
exon-fusion (Le Hir et al., 2001). Splicing occurs more efficiently on 
transcripts transcribed by Pol II (Moore and Proudfoot, 2009). 
 
Polyadenylation: The presence of a poly(A)+ tail on mRNA has been 
known since the 1970s. Proudfoot et al (1976) showed that pre-mRNA 
harbours a hexanucleotide sequence AAUAAA “cleavage signal’ 
(Proudfoot and Brownlee, 1976). Once the pre-mRNA is ready for 
cleavage and polyadenylation, four subunits (WDR33, CPSF160, 
CPSF30 and hFip1) of CPSF (cleavage/polyadenylation specificity 
factor) are reconstituted and then polypeptde WDR33 binds to the 
AAUAAA-containing RNA. Cleavage of the pre-mRNA commences in a 
reaction stimulated by CstF (cleavage stimulation factor) (Schonemann 
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et al., 2014; Hirose et al., 1999). Poly(A) polymerase then adds 
adenosine repeats to the cleaved 3’ end of the nascent mRNA. 
To facilitate these processes, there are a large number of proteins that 
bind to mRNA as it matures and progresses towards export. A family of 
these proteins that bind RNA and facilitate its maturity and nuclear 

























Figure 1.3. Schematic of mRNA processing events. Following 
transcription, the nascent pre-mRNA undergoes processing events 
facilitated and driven by the transcription export complex (TREX). Once 
licensed for export, the mRNP is delivered to the nuclear receptor 
NXF1, flipping open its resting closed state and driving handover of 






1.7. TREX COMPLEX AND mRNA EXPORT ADAPTORS 
Transcription of mRNA is tightly coupled to recruitment of mRNA 
processing and export factors to form export-competent mRNPs 
(Iglesias et al, 2008). The transcription export complex (TREX) in 
humans consists of subunits THOC1, THOC2, THOC5, THOC7, 
ALYREF, TEX1, UAP56, CIP29, ELG, ERH, POLDIP3, CHTOP and 
ZC3H11A (Dufu et al., 2010). In 2009, the Wilson laboratory showed 
that an alternative TREX complex exists in which ALYREF is replaced 
by UIF (UAP56-interacting protein) and both types of TREX complex 
may exist on a single mRNA (Hautbergue et al., 2009; Walsh et al., 
2010). 
The TREX assembly process is driven by the RNA helicase UAP56, and 
three TREX subunits, ALYREF, UIF and CHTOP harbor a short 
transient helical peptide, the UAP56-binding motif (UBM), which acts as 
a binding platform for UAP56 to the rest of TREX (Golovanov et al., 
2006; Chang et al., 2013). Fully assembled TREX bound to mRNA 
provides a signal that nuclear processing is complete and the mRNA is 
licensed for export as an mRNP cargo (Kohler et al., 2007). 
TREX, subsequently, acts as a binding platform for the mRNA export 
receptor NXF1, which itself forms a heterodimer with NXT1 (also known 
as P15). On recruitment of the NXF1:NXT1 heterodimer to TREX 
UAP56 is displaced. In the absence of TREX, NXF1 sequesters its own 
RNA binding domain through an intramolecular interaction [Viphakone 
et al., 2012) and this is important to prevent inappropriate binding and 
export of unspliced mRNA. Once bound to TREX, NXF1 undergoes a 
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conformational change such that the N-terminal RNA binding domain is 
exposed and docks onto the mRNA destined for export (Viphakone et 
al., 2012). This conformational change is dependent on two TREX 
components, ALYREF and THOC5, which directly bind distinct domains 
on NXF1. This increases the binding-affinity of NXF1 to RNA by 4-fold 
(Walsh et al., 2010). Once NXF1 is bound to the mRNA, it escorts the 
mRNP to the nuclear pore, thus the TREX:NXF1 partnership plays a 
central role in the mRNA export pathway.  
	
The mRNA export adaptors provide an important quality assurance link 
between multiple nuclear mRNA processing events and the mRNA 
export receptor NXF1. They are recruited to mRNA through a cascade 
of interactions between each other (as described above). Not all is 
known about the precise interactions of the TREX unit with RNA nor the 
timings of each event; however, some details have been shown 
experimentally.  The TREX complex is poorly recruited to transcripts 
that lack a 5’ cap and those that have not been spliced. This signifies a 
prejudice for ‘quality controlled’ mRNA. Evidence of this is that UAP56 is 
involved in spliceosome assembly, and is recruited to intronless mRNA 
(Walsh et al., 2010). Furthermore, ALYREF is recruited to the 
polyadenylation complex at the 3’ end by PCF11 and ALYREF 
assembles with UAP56 at the 5’end once capping has occurred. This 
frees up a shared binding site on PCF11 for CLP1, which is involved in 
3’ end cleavage (Walsh et al., 2010). Lastly, some evidence suggests 
that certain TREX subunits are required for export of specific mRNAs. 
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For example THOC5 is required for nuclear export of HSP70 (a heat 
shock protein), suggesting that TREX subunits may be pivotal for export 
of differing classes of mRNA (Katahira et al., 2009). 
 
1.8. mRNA EXPORT ADAPTORS AND LINKS TO CANCER 
Studies in the past several years highlight important features of the 
mRNA export process. Experiments on primary tumor specimens 
indicate that many common and specialized mRNA export factors are 
deregulated in cancer (Siddiqui et al., 2012).  Interestingly, this includes 
eukaryotic translation initiation factor 4E (eIF4E), ALYREF, and the THO 
complex. This has positioned these pathways as interesting avenues for 
interrogation as potential therapeutic targets. For example, (at the time 
of referencing) specific targeting of the eIF4E-dependent mRNA export 
pathway in a phase II proof-of-principle trial with ribavirin (an anti-viral 
drug) led to impaired eIF4E-dependent mRNA export correlating with 
remissions in leukemia patients (Siddiqui et al., 2012).   
It has been known for sometime that the TREX component ALYREF 
levels are down-regulated in some cancer cells (Dominquez-Sanchez et 
al., 2009). It is not clear why this is but this finding has led to the quest 
to find other proteins that may share mRNA binding characteristics with 
ALYREF that are brought out of redundancy when levels of ALYREF are 
no longer sufficient. A BLAST search by the Wilson laboratory seeking 
to identify proteins that shared the UAP56 binding site peptide (UBM) 
sequence revealed the two proteins, UIF and LUZP4 (Hautbergue et al., 
2009). Efforts were focused first on UIF, and data quickly showed that 
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UIF could function as an mRNA export adaptor. UIF can bind mRNA, 
UAP56 and NXF1. One interesting difference between ALYREF and UIF 
was the identification that the histone chaperone FACT (facilitates 
chromatin transcription) was required to recruit UIF to mRNA through 
the subunit SSRP1 (but not ALYREF). This became functionally 
intriguing when work by Gasparian et al (2011) on a group of small 
molecule inhibitors known as Curaxins was published. They showed 
that upon inhibition of the FACT molecule by the Curaxins there is an 
up-regulation of p53 and down-regulation of NFkB, and these inhibitors 
can kill cancer cells with excellent selectivity (Gasparian et al., 2011). At 
the time of referencing, Curaxins were in phase 1 clinical trials 
(Gasparian et al., 2011). One hypothesis is that by trapping FACT onto 
DNA, UIF can no longer bind mRNA and support mRNA export in cells 
that may have low levels of ALYREF. 
As well as UIF, our BLAST search for proteins that contained the 
same peptide sequence as ALYREF at the UBM domain [DMSLDDII] 
found a second candidate LUZP4. At the time of project conception, 
LUZP4 (also known as CT-8/HOM-TES-85) was a novel, previously 
uncharacterized cancer testis antigen (CTA). Cancer testis antigens are 
proteins that are normally only expressed in human testes but are 
aberrantly expressed in some cancers (Tureci et al., 2002).  The first 
paper to discuss LUZP4 was by Tureci et al (2002). In this paper, Tureci 
et al (2002) describe qRT-PCR results performed on cDNA extracted 
from tumour specimens, that reveal LUZP4 levels are increased in 
ovarian, lung, glioma and melanoma cancer cells. Tureci et al (2002) 
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postulated that LUZP4 might be “involved in cancer associated 
alterations of transcription or co-transcriptional processes”. Given these 
conclusions that LUZP4 expression is up-regulated in a range of 
cancers, and given that LUZP4 showed homology with the canonical 
mRNA export adaptor ALYREF, we were excited to explore the potential 
for functional overlap with ALYREF within TREX. We generated the 
hypothesis that, like UIF, LUZP4 may continue to export mRNAs in 
some cancer cells that have lost ALYREF. 
 
1.9. CANCER TESTIS ANTIGENS 
At the time when this project was devised, there were 70 known families 
of CTA.  As mentioned above, cancer testis antigens are proteins that 
are normally only expressed in human testes but are aberrantly 
expressed in some cancers. They reside on the X-chromosome and a 
key element in their induction is promoter demethylation (Simpson et al., 
2005). That they display tumour-restricted expression characteristics, 
together with a strong immunogenicity, have made CTAs an attractive 
target for a possible diagnostic and/or prognostic biomarker, or as a 
chemotherapeutic access point (Fratta et al., 2011). 
 
1.10. DNA DAMAGE 
Eukaryotic cell DNA is constantly under attack from exogenous and 
endogenous DNA damage (Houtgraaf et al., 2006). “Genomic instability 
is one of the most pervasive characteristics of tumour cells” (Lord and 
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Ashworth, 2012) and leads to the hallmarks of cancer outlined by 
Hanahan and Weinberg (2011). Genomic instability occurs through the 
combined effect of DNA damage (e.g. UV radiation), tumour-specific 
DNA repair defects (e.g. BRCA1&2 mutations), and a failure to stop/stall 
the cell cycle before damaged DNA is passed on to progenitor cells (e.g. 
p53 mutations) (Lord and Ashworth, 2012). Cells have to develop a 
repertoire of mechanisms to deal with these insults (Pearl et al., 2015; 
Houtgraaf et al., 2006).  Whilst DNA damage and the subsequent 
genomic instability that ensues, drives disease processes such as 
cancer, they also provide windows for therapeutic opportunities (Lord 
and Ashworth, 2012). 
There are numerous types of DNA damage, these include single- and 
double-strand breaks (breaks across DNA), bulky adduct formation 
(covalent bonds between DNA and a chemical), base mismatches (non-
Watson-Crick base-pairing), insertions and deletions, and base 
alkylation (transfer of an alkyl group to a DNA base) (see Figure 1.4) 
(Houtgraaf et al., 2006). Each type of DNA damage is accompanied by 
a unique type of DNA repair mechanism, which may fail or be subject to 
modification. The umbrella term for all DNA repair pathways is the ‘DNA 
damage response’ (DDR). The DDR can largely be subdivided into 
three categories: 1) detection of damage 2) recruitment of DDR factors 
to sites of damage 3) physical repair of damage.  
 
Some of the more familiar DDR pathways include: 1) Base excision 
repair (BER), in which damaged sections of the DNA helix are removed 
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and replaced with ‘healthy’ new DNA. Poly (ADP-ribose) polymerase 1 
and 2 (PARP) are important in this pathway as sensors and signalers of 
damage (Lord and Ashworth, 2012). PARP will be discussed in detail 
below. 2) Nucleotide excision repair (NER) is a similar process to BER 
but is utilised when there are larger breaks in the DNA helix (Lord and 
Ashworth, 2012; Houtgraaf et al., 2006). Typically in these situations the 
actual structure of the helix is distorted. Both of these processes are 
employed in situations of single strand breaks (SSB). When tackling 
double-stranded DNA breaks (DSBs) the main pathways of repair 
involve: 1) non-homologous end joining (NHEJ) and 2) homologous 
recombination (HR). HR involves the use of a complementary sister 
chromatid to provide the template for new DNA synthesis to match that 
which has been damaged and resected, again PARP activity is key in 
this process under certain conditions (e.g. BRCA2 deficient tumours) 
(Bryant et al., 2004). NHEJ involves the direct repair of the broken ends 
by sticking them back together. NHEJ is an ongoing process throughout 
the cell cycle; however, HR is restricted to S and G2 phases (Lord and 
Ashworth, 2012). Mismatch repair deals with insertion and deletion 
loops that form during DNA replication. These cause mismatches 
between bases.  
Furthering our understanding of the sequence of DNA damage, and 
learning how we might predict DNA damage behaviour and rescue such 
defects are all part of the process of utilizing these pathways to benefit 









Figure 1.4. Diagram summarizing the DNA damage pathways. Adapted 
from Lord CJ, Ashworth A. The DNA damage response and cancer 









1.11. POST TRANSLATIONAL MODIFICATIONS  
In recent decades the scientific community has discovered that the 
human proteome contains vastly more proteins than are accounted for 
by genes in the genome (International Human Genome Sequencing 
Consortium, 2004). Genomic recombination and alternative splicing are 
examples of how the resultant proteins coded for by a single gene can 
be numerous and varied (Ayubi and Van De Ven, 1996) (Figure 1.5). 
Post-translational modifications (PTMs) are responsible for some of 
these variances. These changes affect protein activity, localization and 
function.  PTMs are often initiated by an external stimulus such as heat 
shock or DNA damage. These stimuli may then engage enzymes such 
as kinases, phosphatases, ligases and transferases to add or remove 
functional groups and subunits from proteins (ThermoScientific, 2015). 
 
The PTM family consists of phosphorylation, acetylation, ubiquination, 
methylation, glycosylation and ribosylation amongst others. This work 
focuses on poly (ADP-ribosyl)ation (also known as PARylation) as a 
method of gene regulation. Poly (ADP-ribosyl)ation is one of many post-
translational modifications (PTMs) that can alter protein function. To 
achieve this change in function, the enzyme poly(ADP-ribose) 
polymerase (PARP) adds one or many ribose moieties (can be in the 
order of 100’s) onto target proteins (Fahrer et al., 2007). This entails the 
rapid synthesis of long (sometimes 200-300 copies), branched PAR 
chains (poly (ADP-ribose)) from nicotinamide adenine dinucleotide 
(NAD+) (Satoh and Lindahl, 1992; Jungmichel et al., 2013).  The 
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glycosidic bonds of the ribose chains may then be cleaved by poly 
(ADP-ribose) glycohydrolase (PARG). Poly (ADP-ribosyl)ation is a 
transient and cyclical process, with a half-life of between 1 minute and 8 
hours (Alvarez-Gonzalez and Althaus, 1989). Downstream effects are 
similar to those seen by PTMs such as methylation and ubiquitinisation 
(e.g. altered cellular location, altered protein-protein interactions or 
degradation). Poy(ADP-robose) (PAR) is rapidly produced at DNA 
breaks by PARP. This triggers local chromatin relaxation and 
recruitment of repair factors. Many repair factors have a strong affinity 
for PAR. The quantity of PAR produced at these sites is reflective of the 
severity of the insult, and contributes to the cellular decision of whether 
to initiate survival or cell death programmes (Mortusewicz et al., 2011). 
In particular, PARP has been shown to be involved in repairing stalled 
replication forks (Bryant H et al., 2009), which has been recognized as 
an important mechanism for preventing carcinogenesis (Bartkova et al., 
2006).  
Mass spectrometry based proteome wide studies of poly (ADP-
ribosyl)ation targets by Jungmichel et al (2013) and Zhang et al (2013). 
Identified numerous new targets for this post-translational modification 
including a large number of RNA binding proteins and proteins involved 
in RNA processing.  
In one study (Zhang et al., 2013) PARylated peptides arising from TREX 
subunits account for 20% of all identified sites indicating that mRNA 
export factors are a major intracellular target for poly (ADP-ribosyl)ation. 
PARylation sites were identified for the TREX subunits ALYREF, 
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CHTOP, POLDIP3, ERH, UIF and within NXF1 and NXT1.  
Poly (ADP-ribosyl)ation has been shown to occur as part of the DNA 
damage response mechanism (Fathers et al., 2012) and deregulation of 
this process may render cells more sensitive to noxious stimuli. We 
hypothesized that mRNA export factors may be subject to functional 
























Figure 1.5. Picture illustrating the evolving complexities of the 
proteome. Adapted from: Overview of Post Translational Modifications, 
















Figure 1.6. Model showing the transfer of ribose moieties on to target 
proteins by PARP, and their removal by PARG. Image adapted from 
Mueller-Dieckmann C, Kernstock S, Lisurek M et al. The structure of 
human ADP-ribosylhydrolase 3 (ARH3) provides insights into the 







1.12. “SEEING IS BELIEVING”: MODELS FOR 
MONITORING mRNA EXPORT PATTERNS 
RNA localization is the process by which a cell transports and anchors 
specific RNA transcripts and it is dynamically regulated in cells (Blower, 
2013; Strack et al., 2013).  Appropriate localization can make cells more 
efficient (e.g. localizing mRNAs near sites of active translation) and 
prevent harmful effects (e.g. toxic accumulation at one site) (Blower, 
2013). Understanding the cellular localization of RNA can deepen our 
knowledge of the fate of particular RNAs. In cancer and other diseases, 
RNA transcripts can be found in the ‘wrong’ place (Baker, 2012) and 
where the RNA is localized, and under what conditions, may help inform 
us about cellular events. For example, observing mRNA 
nuclear/cytoplasmic export blocks during RNAi studies. 
RNA localization can be studied using fluorescence in situ hybridisation 
(FISH) (which uses RNA transcript specific probes that consist of 
complementary oligonucleotides tagged to a fluorophore (Baker, 2012). 
FISH has typically relied on cells being fixed on a microscope slide (i.e. 
there is no ‘live’ image capture).  Other assays include MS2 or GFP. 
MS2 studies involve the co-expression of an MS2-RNA binding protein 
with a tagged fluorophore and RNA with MS2 binding motifs. Upon 
binding one another a fluorescence signal is released denoting the 
location of the RNA (Broude, 2011). GFP (green-fluorescent protein) is 
a protein composed of approximately 230 amino acids and exhibits a 
green fluorescence when exposed to/excited by blue light (Tsuji, 2010). 
The protein was originally extracted from jellyfish (mCherry, a red 
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fluorophore, is a derivative of this protein).  With the GFP tag, 
expression vectors for GFP fusion proteins can be transfected into living 
cells and then monitored for localization in different cells and under 
different conditions (Chudakov et al. 2010).  
 
In recent years, the Jaffrey lab at Cornel University developed a novel 
RNA monitoring system known as Spinach. Spinach is a 98-nucleotide 
RNA aptamer that binds 3,5-difluoro-4-hydroxybenzylidene 
imidazolinone (DFHBI), a small GFP-like molecule that is non-
fluorescent on its own, but in complexing Spinach forms a bright signal 
(Strack et al., 2013). It can be genetically encoded into RNA’s in order to 
image RNA in living cells. Spinach2 is a second-generation construct 
that has been modified with more folding complexity to provide a greater 
level of thermal stability and can fluoresce more brightly (Strack et al., 
2013). 
The Spinach system may allow the monitoring of RNA export in living 
cells but little work has been done to map mRNA export using the 
Spinach2 system. Our final aim in this project was to try and record 
mRNA export blocks in conditions of DNA damage or in TREX 
component RNAi cell lines.  
 
 


















1.13. THE AIMS OF THIS PhD 
The clinical need of a reliable biomarker for BC and for new treatment 
modalities for cancer in general provide a great research opportunity. 
At the commencement of this project, there has been much work 
interrogating possible non-invasive biomarker for BC that might replace 
the gold standard of cystoscopy. In addition, BC treatment is expensive 
(NMIBC) and morbid (MIBC) and current chemotherapy regimes for 
metastatic MIBC achieve unsatisfactory results.  
 
We believed that LUZP4 might provide a potential target that may 
provide an answer to both of these needs. Furthermore, research into 
the links between types of DNA damage and the onset of cancer is an 
ever evolving and exciting field, and this project aims to push forward 
the frontiers of this branch of molecular biology. In particular, we believe 
that mRNA export plays a crucial role in this relationship. 
 
Therefore, my project aims are: 
1) To evaluate the expression pattern of the mRNA export adaptor LUZP4 
in a range of cancer cell lines and tissue types 
2) To investigate the potential of LUZP4 as a biomarker experiments on 
human urine and bladder tissue 
3) To examine the extent to which cancer tissues lose expression of 
ALYREF as an mRNA exporter 
4) To interrogate the impact of DNA damage on TREX assembly and 
function 
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5) To determine whether the post-translational modification, poly (ADP-
ribosyl)ation, is responsible for observed changes in mRNA export upon 
DNA damage. 
6) To develop a model in the Wilson laboratory for monitoring real-time 
mRNA export using the Spinach-2 system as a means of investigating 
mRNA export patterns under differing conditions of stress. 
 
However, epidemiological data suggest that the phenotype of BC is 
changing. As such, I wanted to place these findings into a contemporary 
picture of BC. Thus, I also undertook systemic reviews of the current 











Chapter 2: Materials and Methods 
2.1 MATERIALS 
2.1.1. CELL LINES 
Bladder Cancer cell lines: 





Bladder Unknown Epithelial (TCC) 
5637 Bladder Unknown Epithelial (TCC) 
SW780 Bladder Lung Epithelial (TCC) 
HT1376 Bladder Unknown Epithelial (TCC) 
SCaBER Bladder Metastatic  Epithelial (SCC) 
HT1197 Bladder Unknown Epithelial (TCC) 
TCC-SUP Bladder Bone and Brain Epithelial (TCC) 
 
NCI-60 cell lines: 
Cell line Body part Metastatic at 
harvest 
Cell type 
MDA-MB-435 Skin Lungs Fibroblast (melanoma) 
RT112 Bladder No Epithelial 
RT4 Bladder Lungs Epithelial 
EJ Bladder Lungs Epithelial 
DU 145 Prostate Bone Epithelial 
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PC-3 Prostate Bone Epithelial 
SK-0V3 Ovary Lymph node Epithelial 
T47D Breast Yes, unknown 
site 
Epithelial 
HS578T Breast Yes, unknown 
site 
Epithelial 
HCT116 Colon Liver Epithelial 
HT29 Colon Liver Epithelial 
SW620 Colon Lymph node Epithelial 
COLO205 Colon Yes, unknown 
site 
Epithelial 
A549 Lung No Epithelial 
NCIH460 Lung Lymph node Epithelial (large cell) 
U937 Blood Unknown Histiocytic/myeloid 
K562 Blood No Lymphoblast 
HL-60 Blood Yes, unknown 
site 
Lymphoblast 
THP-1 Blood Unknown Monocyte 
U87-MG Brain No Epithelial 
 
Routine cell lines used in the Wilson Lab: 
Cell line Origin Use 
293T Kidney Negative Control for 
LUZP4 experiments 
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MeWo Skin Positive Control for 
LUZP4 experiments 
HeLa Cervical Fluorescence in Situ 
Hybridization 
Cos-7 Monkey Spinach 2 experiments 
 
2.1.2. BACTERIAL STRAINS 
Stain Genotype Use 
DH5alpha E.coli supE44 Molecular cloning 
BL21 (RP) E.coli Recombinant 
protein production 
 
Antibiotic Final Concentration 
Ampicillin 100 µg/ml 
Kanamycin 50 µg/ml (30 µg/ml in LB agar) 
Spectinomycin 50 µg/ml 
Chloramphenicol 34 µg/ml 
 
2.1.3. GROWTH MEDIA 
 
All media was sterilized by autoclaving. 
Luria Bertani (LB): 10 % Tryptone, 10 % NaCl, 5 % yeast extract. 
LB Agar: As above, with addition of 2 % Agar w/v. 
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Terrific Broth (TB): 12 g/L Tryptone, 24 g/L, 24 g/L Yeast Extract, 4 




PET-24b Prokaryotic expression vector, T7 
promoter, kanamycin resistance, 
3’ 6 x His-tag. Used for 
expression of His-tagged 
recombinant proteins in E.Coli, 
induced by IPTG 
pGEX-6P1 Prokaryotic expression vector, 
ampicillin resistance, 5’GST-tag. 
Used for expression of GST-
tagged recombinant proteins in 
E.coli, induced by IPTG. 
pcDNA-FRT-TO Mammalian expression vector  
containing an FRT site for Flp 
recombinase-dependent stable 
integration into the Flp-In 293 
genome. CMV promoter, 2 
tetracycline operator sequences, 





 All buffers requiring sterilization were autoclaved. Those requiring 
filtration we passed through a 0.2 µm filter. 
 
DNA and RNA protocol buffers 
• 6 x DNA loading buffer: 0.25 % (w/v) Xylene Cyanol; 0.25 % (w/v) 
Bromophenol Blue; 30 %  (v/v) Glycerol.  
• 1 x TBE: 90 mM Tris; 90 mM boric acid; 2.5 mM EDTA, pH 8.0. 
SDS-PAGE/western buffers 
• 4 x SDS-PAGE Loading Buffer: 200 mM Tris-HCl, pH 6.8; 1 % (w/v) 
Bromophenol Blue; 50 % (v/v) glycerol; 10 % (w/v) SDS. 
• 4 x SDS-PAGE Stacking Gel Buffer: 0.5 M Tris-HCl, pH 6.8; 0.15% 
(w/v) SDS. 
• 4 x SDS-PAGE Resolving Gel Buffer: 1.5 M Tris-HCl, pH 8.8; 0.15% 
(w/v) SDS. 
• SDS PAGE Running Buffer: 25 mM Tris; 250 mM glycine; 0.1 % (w/v) 
sodium dodecyl sulphate (SDS). 
selection. Hygromycin resistance 
for stable integration selection 
pCI-neo Mammalian expression vector, 
CMV promoter, neomycin 
resistance 
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• Coomassie Brilliant Blue Stain: 0.1 % (w/v) Coomassie Brilliant Blue 
R-250, 40 % Methanol, 10 % Acetic Acid. 
• Destain solution: 40 % (v/v) Methanol, 10 % (v/v) Acetic Acid 
• Transfer Buffer: 39 mM Glycine, 48 mM Tris, 0.037 % (w/v) SDS, 20 % 
Methanol. 
Miscellaneous Buffers  
• 1 x PBS (phosphate buffered saline): 137 mM NaCl; 2.7 mM KCl, 4.3 
mM Na2P04; and 1.47 mM KH2P04. pH to 7.4 using HCl. 0.1% (v/v) 
Tween-20 added to make 1 x PBS-Tween (PBST). 
• 1 x TBS (Tris buffered saline): 50 mM Tris-HCl, pH 7.5; 150 mM NaCl. 
2 % Tween-20 added to make 1 x TBST. 
• 3.7% Paraformaldehyde Fixing Solution: 10 ml 1 x PBS, 33.4 ml 
11.1% Paraformaldehyde (pH 7.4), 0.6 ml 30 % Triton X-100, 56 ml 
Millipore-filled H20. 
• ECL Solution #1: 100 mM Tris-HCl pH 8.5, 2.5 mM luminol; 400 µM p-
coumaric acid; ECL Solution #2: 100 mM Tris-HCl, pH 8.5; 5.3 mM 
hydrogen peroxide. 
• FISH fix solution: A boiled mixture of 33.4 ml Millipore-filtered H20, 3.7 
g Paraformaldehyde, 20 mls 5 x PBS is made above pH 9 (1 M NaOH is 
used to achieve this). Once dissolved 180 µL Tritonx100 is added along 
with 1 M HCl acid to achieve a final pH of 7.4. Final this is filtered using 
0.2 µM filter and the volume is made up to 100 mls using Millipore-
filtered H20. 
• FISH hybridization buffer: for 100 mls; 20 mls formaldehyde, 10 mls of 
20 x saline sodium citrate, 10 g dextran sulphate, 1 g bovine serum 
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albumin and made up to 100 mls with Millipore-filtered H20 and stored at 
4oC or 20oC. When ready for use the following was added; 1 ng/µL of dt-
Cy3, 0.5 µg/ml ssDNA, 0.5 µg/µL tRNA. 
• Crystal Violet Colony Forming Assay Stain: 0.5 g Crystal Violet 
(0.05% w/v) 27 ml 37 % Formaldehyde (1%), 10 ml 10 x PBS (1x), 10 
ml Methanol (1 %), up to 1 L with Millipore-filtered H20. 
• TFB1 buffer: 30 mM KOAc, 50 mM MnCl2, 100 mM KCl, 10 mM CaCl2, 
15% glycerol, pH 7.0. TFB2 buffer: 10 mM MOPS, 75 mM CaCl2, 10 
mM KCl, 20 % glycerol, pH 7.0. 
• Cobalt buffers: Loading: 50 mM Tris-HCl (pH 8.0), 1 M NaCl, 5 mM 
Imidazole, 0.5 % Triton X-100, 10% glycerol. Wash: 50 mM Tris-HCl 
(pH 8.0), 1 M NaCl, 10 mM Imidazole, 0.5 % Triton X-100, 10% glycerol. 
Elution: 50 mM Tris-HCl, 0.5 M NaCl, 200 mM Imidazole, 0.5 % Triton 
X-100, 10% glycerol. 
 
2.1.6. MOLECULAR BIOLOGY KITS 
 
• Small scale plasmid DNA purification: QIAGEN Mini spin preparation 
kit 
• Midi scale plasmid DNA purification: QIAGEN Midi spin preparation 
kit 
• DNA extraction from agarose: QIAGEN Gel Extraction Kit 
• In vitro transcription/translation: T7 Quick Coupled 
Transcription/Translation system (Promega) 
• CLICK-iT: Life technologies nascent RNA capture kit.  
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2.2 METHODS 
2.2.1 SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Both systematic reviews and meta-analyses were conducted according 
to accepted protocols (PRISMA) to search recognized databases 
(PubMed, Embase, Medline). Meta-analysis was performed using the 
STATA statistical suite (Version 12.0) to generate risk ratios for the 
outcome of interest. 
 
2.2.2 MOLECULAR BIOLOGY 
 
Polymerase chain reactions (PCR) 
50 µl reactions were used containing 10-100 ng DNA template, 1 x 
reaction buffer, 200 µM dNTP, 0.5 µM each for forward and reverse 
primers, and 1 unit of DNA polymerase (Biotaq, Bioline). We then used 
a mastercycler (Eppendorf) to cycle the reactions using the protocol 
below: 
Step Cycles Temperature (oC) Time (minutes) 
1 1 96-98 (Initial Denaturation) 0.5-1 
2 25-30 96-98 (Denaturation) 0.5 
56-60 (Annealing) 0.5 
72 (Extension) 0.5/Kb product 
length 




DNA agarose gels 
Gels were made using TBE agarose at concentrations of 0.4 to 4% 
concentrations with the addition of 20µg/ml of Ethidium Bromide. Gel 
mixtures were typically heated until boiling in a microwave oven before 
being poured into a gel-cassette and allowed to cool solid.  
 
Cloning 
This is the process of introducing a DNA fragment (insert) into a plasmid 
(vector).  PCR is most often used to produce the insert but they can also 
be liberated from a stock vector in order to transfer it to a new host 
vector with different genetic properties. 
The host plasmids were linearized by digestion with the pre-designed 
restriction enzymes. 5 µg of plasmid was digested for 2 hours at 37oC 
with 50 units (U) of each enzyme, followed by 30 minutes incubation 
with calf intestinal alkaline (CIAP) (1µl at 37oC). The CIAP prevents the 
plasmid from re-ligating with itself (removes the 5’ phosphate). Following 
this, the plasmid DNA is purified by phenol-chloroform extraction and 
ethanol precipitation.  
In conditions where the required insert was excised from an existing 
plasmid, to isolate the desired DNA fragment, the digestion products 
were separated by agarose gel electrophoresis. The desired DNA 
fragment was cut from the agarose gel with a sterile blade, and then 
purified using QIAGEN’s gel extraction kit. The resultant DNA was 
ethanol precipitated and re-suspended in Millipore-filtered H20. 
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Where insert fragments were generated by PCR, the primers required 
were designed with the required restriction sites juxtaposed by 6 
additional 5’ bases. These were incorporated to provide a ‘landing 
platform’ for the restriction enzymes. After amplification using the above 
protocol, the reaction mix was gel extracted and digested overnight at 
37oC with 100 U of the chosen restriction enzymes. Digestion reactions 
were phenol-chloroform extracted and ethanol precipitated before re-
suspension with Millipore-filtered H20. 
 







To determine relative DNA concentrations, and to ensure that 
linearization was complete, samples were run on an agarose gel. After 
this, 100 ng of linear vector was added to the insert DNA, along with 10 
U of T4 ligase (Roche) in 1x T4 ligase buffer (Roche). These ligation 
reactions were standardly incubated at 16oC overnight. Half of the 
ligation mix (typically 5-10 µl) was transformed into competent E.coli. 
 
Phenol chloroform-isoamyl alcohol DNA purification 
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One volume of phenol chloro-isomyl alcohol (25:24:1, pH 6.6/8) was 
added to DNA solution. Mixture was vortexed for 1 minute and then 
centrifuged for 5 minutes at 13,000 rpm. The upper phase was 
transferred to a fresh tube and 2.5-3 volumes of 100% ethanol were 
added. 3 M Sodium acetate (pH 5.3) was also added to a final volume of 
10 %. This mixture was incubated on ice or -20oC for 20 minutes and 
then centrifuged for 20 minutes 13,000 rpm. The supernatant was 
removed and discarded before 1 ml of 70% ethanol was added. The 
sample was then centrifuged again for 20 minutes at 13,000 rpm. The 
supernatant was discarded and the pellet was air-dried. Dried pellets 
were then re-suspended in the required volume of Millipore-filtered H20. 
 
Isolation of plasmid DNA from E.Coli 
For spin-prep/mini-preps, 3 mls of LB medium containing the correct 
selection antibiotic was inoculated with a single E.coli colony. The 
culture was then placed in a rotating incubator at 37oC overnight. For 
midi-preps, 50 mls of LB medium was used. Before storage at -20oC, 
the DNA plasmid was purified using the appropriate QIAGEN kit. 
 
DNA restriction digest 
Restriction digests were performed using the optimal buffer/enzyme 
combination as per the manufacturer (Thermoscientific). The enzyme 
content never exceeded 10 %. This was to avoid an excess glycerol 
concentration. Digestions were carried out at 37oC for 1 hour unless 
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fast-digest enzymes were available, in which case restrictions lasted for 
30-45 minutes.  
 
Chemically competent E.Coli 
Overnight cultures were prepared by inoculating the appropriate strain in 
10 ml LB then incubated at 37oC. This culture was used to inoculate 500 
ml LB to a final density of OD600 = 0.05 and incubated at 37oC until 
OD600 = 0.48. The cells were placed on ice for 10 minutes before being 
centrifuged at 600 x G at 4oC for 10 minutes in pre-sterilized centrifuge 
pots. The resulting pellets were re-suspended in 250 ml, ice cold, filter-
sterilized TFB1 and then left on ice for 10 minutes before being 
centrifuged again. The resulting pellet was then gently re-suspended in 
25 ml ice cold, filter-sterilized TFB2 and left on ice for 10 minutes. The 
suspension was then aliquoted into sterile, pre-cooled eppendorf tubes 
kept in a tray half submerged in liquid nitrogen. The tubes were then 
flash frozen in liquid nitrogen and stored at -80oC. 
 
Transforming chemically competent E.Coli 
DH5alpha or BL21 (RP) cells were defrosted on ice for 20 minutes 
alongside the defrosting aliquot of DNA to be transformed. After 20 
minutes, the DNA was added to the cells, mixed gently and left to rest 
on ice for a further 20 minutes. The cells were then subjected to a heat-
shock for 5 minutes at 37oC or 30 seconds at 42oC and recovered on ice 
for 10 minutes. Following this 900 µl of sterile LB media was added to 
the cells and they were placed in a 37oC incubator, rotating at 200 rpm 
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for 1 hour. The cells were then centrifuged at 7200 rpm for 1 minute. 
900 µl of the supernatant was discarded and the cell pellet was then 
resuspended in the remaining supernatant and spread over pre-warmed 
and pre-dried LB agar plates made with the correct antibiotic selection. 
 
In vitro site-directed mutagenesis 
This method uses standard PCR to introduce a single or multiple 
nucleotide changes into a wild-type sequence. Primers were designed 
to mutate the target nucleotides by positioning said target in the centre 
of flanking nucleotides from the WT sequence (between 18 and 24 
depending on the number of nucleotides to be mutated) to ensure 
adequate annealing. Reactions contained: 100 ng DNA plasmid, 125 ng 
each primer, 200 µM dNTP, 2.5 Pfu Turbo polymerase and 1 x Pfu 
Turbo polymerase buffer in a final volume of 50 µl.   















Following this, samples were Dpn1treated for 1 hour at 37oC, with the 
aim of removing methylated DNA. These reactions were then ethanol 
precipitated and transformed into E.Coli (DH5alpha). Colonies were sent 
for sequencing. 
 
Mutations were made using site directed mutagenesis with the following 
sequence primers: 






UAP56 with mutation KDAQRRIL: 
5’ TATCAGCAGTTTAAAGATGCGCAACGACGAATTCTTGTG 
3’ CACAAGAATTCGTCGTTGCGCATCTTTAAACTGCTGATA 








Throughout the experiments 6 %-15 % acrylamide gels were used. 
These consisted of an upper and a lower gel component containing a 
variable mixture of deionized water, 30 % acrom/0.8 % biscocryl 





Western blotting   
40 µg of whole cell lysates were added to 4 x SDS page loading buffer 
and boiled at 90 degrees for 3 minutes to denature the proteins. 
Samples were then loaded onto the polyacrylamide gel and run at 35 
mAmps for approximately 1 hour or until the migration of the dye was 
deemed complete. The gel was then transferred onto a nitrocellulose 
membrane using 150 mAmps current for 1-2 hours. Membranes were 
then incubated in 5% milk (made in TBST) for 1 hour and then washed 
in TBST three times. Membranes were then incubated in milk containing 
a primary and relevant secondary each for 1 hour, followed by three 
more TBST washes each for 5 minutes. Finally, the membrane was 
washed in 1 ml of ECL 1 & and 1 ml of ECL 2 (mixed) for 1 minute and 
then the membrane was exposed on the Biorad gel-doc system to look 
for protein bands. 
 
Total RNA extraction and quantitative real time polymerase chain 
reactions 
Cells pellets were lysed using reporter lysis buffer (5x) and water. 230 
mls of lysate per cell line was kept on ice in a micro-centrifuge 
(eppendorff) tube and mixed in trizol at a ratio of 1:3. Once 
homogenized, 200ul of chloroform was added to each cell line and 
homogenized by repeated shaking and inversions of the eppendorff 
tubes. Each was then left to stand for 5 minutes at room temperature 
before being centrifuged at 11200 rcf for 10 minutes. All supernatant 
was then transferred to new eppendorffs and added to isopropanol 
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(volume 1:1) and 0.5 µl of glycogen. This solution was again 
homogenized by several inversions before a further 10 minute 
incubation at room temperature and a centrifugation at 16100 rcf. The 
new supernatant was discarded and the cell pellet washed with 1 ml of 
70 % ethanol. The pellets were then spun at 16100 rcf for 5 minutes. 
The supernatant was again discarded and the cell pellet was dried at 
room temp for 15 minutes. 
The next step in RNA extraction and cDNA synthesis was DNAse 
treatment of the pellets. Each pellet was re-suspended in a mix of 44 µl 
water and 5 µl 10x buffer that was homogenized by pipetting. 1µl DNA 1 
Roche (RNase-free) was added and gently homogenized followed by a 
30min incubation at 37c. Once incubated a further 50 µl of water and 
100 µl of RNA phenol (pH4.7) was added and vortexed to form a white 
emulsion. The mix was then centrifuged at 16.1 x 1000 rcf for 5 minutes. 
90 µl of supernatant was then transferred to new tubes for precipitation 
with 10 µl sodium acetate (pH 5.8), 400 µl of 100 % ethanol and 0.5 µl 
glycogen. This was centrifuged for 30 minutes at 16100 rcf. The pellet 
was then washed in 70 % ethanol and spun for a further 8 minutes at 
16100 rcf and air dried for 15 minutes following removal of the 
supernatant. 
RNA concentrations were then calculated using the Nanodrop 
(ThermoScientific). Pellets were re-suspended in 10 µl of water and 1 µl 
samples run through the Nanodrop. Once concentrations were known, 
cDNA synthesis was conducted by first adding polyDN to the RNA mix 
and denaturing at 70oC in the PCR machine, followed by the addition of 
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4 µl buffer 5x (Bioscript), 4 µl of 250 mM dNTPs and 0.5 µl reverse 
transcriptase (Bioscript) and a run of PCR. The PCR programme was 
set to incubate at 25oC for 10 minutes, perform cDNA synthesis for 1 
hour by incubating at 42oC, followed by inactivation of reverse 
transcriptase by incubating for 10 minutes at 70oC.  
Once the cDNA was produced, samples were diluted by the addition of 
20 µl-80 µL of deionized water and homogenized. A qRT-PCR robot 
was then used to mix 4 primer stocks (1 µg/µl diluted to 20 x final), with 
Sybr green (sensimix 2 x, Bioline) and water. 10 µl final volume 
samples, in duplicates, of each cell line plus a no template control 
sample was loaded to each mix in the qRT-PCR tubes and a ‘three 
steps with melt’ qRT-PCR programme was cycled to provide our results. 
 
LUZP4 RT-PCR primers were:  
Forward: 5’-GGAGAGGCTACTCAAGATGCAGAAGC-3’  
Reverse: 5’-GAGATCACTCTGAGTGTCCACAAGATCTCC-3’. 
U1 RT-PCR primers were: 




Cell pellets were resuspended in 1 x PBS + 0.1 % Tween (PBST) using 
at least 5 times the pellet volume. The suspension was supplemented 
with protease inhibitors before sonicating on ice at 15 microns to lyse 
the cells. The lysate was then centrifuged at 16000 rcf at 4oC to pellet 
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the cell debris and the supernatant was applied to glutathione 
sepharose beads. This mix was incubated at 4oC on a rotating wheel for 
1 hour. The beads were then pelleted by centrifugation at 400 rcf and 
the supernatant discarded. Beads were then washed 3 times with ice 
cold PBST. Proteins were then eluted by the addition of GSH elution 
buffer at 2.5 times the bed volume of the beads and then incubated on 
ice for 15 minutes with regular agitation. After centrifugation at 400 rcf, 
the supernatant was transferred to a fresh tube, and then stored at 4oC 
or -80oC. 
 
6 x Histidine-Tagged Proteins 
Cell pellets were re-suspended in cobalt loading buffer and then 
supplemented with protease inhibitors before sonication and 
centrifugation (as per GST-Tagged Proteins). This time, the supernatant 
was applied to Cobalt sepharose beads and incubated on a rotating 
wheel for 1 hour at 4oC. The beads were then washed with a cobalt 
wash buffer. Proteins were eluted using a cobalt elution buffer and 
incubated for 30 minutes on ice with regular agitation. The supernatant 
was then stored at 4oC or -80oC. 
 
Gibson Assembly 
This facilitates the joining of overlapping DNA fragments in a single 
isothermal reaction.  In the first step, an exonuclease creates single 
stranded 3’ over-hangs to permit annealing of fragments that share 
complementarity at one end (overlap). Steps 2 and 3 involve a DNA 
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polymerase and ligase to fill fragment gaps and seal the nicks in the 
DNA [Gibson Assembly Mastermix guide Vsn 3.2].  
 
RNA interference 
RNAi hairpins were designed and constructed according to the Block-IT 
kit manual (Invitrogen). The designed pre-miRNA sequences were 
cloned into pcDNA 6.2GW miR vector. When transfected into cells, 
these vectors were used to “knockdown” the levels of the mRNA for 
which the pre-miRNA was specific. In order to create a stable RNAi cell 




Cell lines were transfected with the appropriate concentrations of DNA 
plasmid in accordance to manufacturer’s guidelines using Turbofect 
(gelifesciences) as a transfection agent diluted in Hyclone MEM-RS 
media (Thermoscientific). Cells were typically transfected one day 
following splitting and plating. 
 
Stable cell lines  
This involves the production of a stable mammalian cell line exhibiting 
tetracycline inducible expression of a gene of interest from a specific 
genomic location [LifeTechnolgies]. To do this, an expression vector for 
the gene of interest is integrated into the genome via a Flp 
recombinase-mediated DNA recombination at the FRT site under the 
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control of a tetracycline-inducible promoter [O’Gorman et al, 
Science.1991] 
On day zero the FlpIn-293 cells were split in DMEM+FCS-Tetracycline 
free media without any selection drugs, into a 6cm dish. One day 
following this, the cells were transfected with 4.6 µg of recombinase 
(pPGKFLPobpA) and 2.4 µg of FRT vector DNAs with 12 µL of 
Turbofect and 600 µL of Hyclone MEM-RS media. On day two, the 
media was renewed with DMEM+FCS-Tetracycline free without 
selection antibiotics. On the morning of day 3 the cells were split into 2 x 
10cm dishes in DMEM+FCS-Tetracycline free media. On the same 
afternoon, the medium was changed to selection media (DMEM+FCS-
Tetracycline free media + Hygromycin 0.1 mg/mL and Blastocidin 
15ug/mL). Two days later, all dead cells were removed and the 
selection media was renewed. After 5 further days, the medium was 
again renewed. At this stage, the plates were inspected to ensure that 
all cells appeared dead. Over the next two weeks, the plates were 
observed for the formation of new patches of cells. Once these were 
confluent, the dishes were split into a T75 flask.  If specific colonies 
were to be tested and used (as with the PARG RNAi cell line), then 
instead of splitting the cells into a T75 flask, cloning disks (Sigma) 
coated in trypsin were placed on a few identified colonies in the 10cm 
dishes. These disks were then placed in a 24 well plate with selection 
media. Following this, each colony was grown further and put into 
routine cell culture. Some of the cells were siphoned off, induced with 
tetracycline and tested for knockdown efficiency. 
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The sequence of cloned inserts was checked by industrial DNA 
sequencing at Source biosciences’ Nottingham laboratory. Various 
primers were used, including stock primers for T7/T3 promoters. Inserts 
were shipped at 100 µg/µL in 10 µL total volume. Fidelity of the 
sequence was checked using SerialCloner. 
 
2.2.3. BIOCHEMISTRY 
 In vitro GST-pulldown assays 
GST-tagged proteins were purified as above and used as a target for 
radiolabelled proteins produced in rabbit reticulocyte lysate using the T7 
Quick Coupled Transcription/Translation system (Promega).  
Reactions were conducted on ice using RNase free eppendorf tubes. 
Reactions in 10 µl final volume contained: 1.5 µl plasmid DNA (usually 
200 ng), 0.5 µl S35 methionine and 8 µl of reticulocyte lysate from the 
Promega kit. The reaction mix was homogenized and then incubated at 
30oC for 1 ½ hours at room temp. 1-2 µl of this reaction mix was kept as 
an input for the pulldown and mixed with RNase-free water and 4 x SDS 
page loading buffer to a final volume of 10 µl. The remaining lysate was 
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incubated on a rotating wheel at 4oC for 1 hour in a bead mixture with 
the purified GST-tagged proteins (10-20 µl bead volume) in 400 µl of 
PBST binding buffer. When investigating direct binding between 
proteins, 10 µg/ml of RNase A was added to ensure interactions were 
not bridged by RNA. 
Following this incubation, the beads were washed x 3 with 1 ml of 
PBST. After the final wash the supernatant was discarded and the 
beads were dried using gel-loading tips to ensure no unspecific binders 
were included in the elution. Elutions were performed using 3 x bed 
volume of 1 x SDS page loading buffer and incubating the mixture at 
95oC for 5 minutes. The mixture was then centrifuged at 400 rcf for 1 
minute. Using a gel-loading tip to avoid inadvertently aspirating beads, 2 
x bed volume of supernatant was extracted and placed in a new 
eppendorf ready for loading onto a polyacrylamide gel. Following gel 
electrophoresis the gel was incubated in Coomassie Brilliant Blue stain 
for 30 minutes, followed by de-staining (using a methanol/acetic acid 
solution) and gel drying.  The dried gel was then exposed to a phosphor 
screen, typically for at least 16 hours. The screen was then scanned in a 
phosphorimager (Biorad) to produce the phosphor image. 
 
In vivo Immunoprecipitations 
Protein glutathione sepharose beads were incubated with 10 µg of 
antibody at 4 oC over night the night before the IP. Two 15 cm dishes 
per condition of 293T cells were also plated the day before the 
experiment. Each plate was lysed in 5 mls of IP lysis buffer (2.5 mls 1 M 
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Hepes-NaOH pH 7.5, 1.67 ml 3M NaCl, 0.1 ml 0.5 M Edta pH 8.0, 0.25 
ml triton x 100, 5 ml glycerol 100 %, 50 µl 1M DTT), and spun down at 
16100 rcf for 3 minutes. The concentration of protein in the supernatant 
was ascertained by spectography and the maximum, equal, possible 
amount loaded across conditions and added to 50 µl of protein 
glutathione sepharose beads that were pre-washed three times in IP 
lysis buffer. Next was an incubation on protein glutathione sepharose 
beads for 1 hour at 4 degrees. IP wash buffer (IP lysis buffer at pH 8.0 
with 5 mM imidazole) was applied three times. The protein was eluted 
off the beads using an acid shock of 90 µl of 0.5 M L-arginine HCL pH 
3.5 applied for 2 minutes and then spun down for a further 1 minute at 
400 rcf. Eluate was buffered by addition of 1.75 µl 1.5M TRIS-HCl 
pH8.8. 20 µl of protein eluate was then added to 4x SDS page loading 
buffer and a western blot was performed as above. 
 
2.2.4. CELL BIOLOGY 
Tissue culture 
Tissue culture was performed on a twice-weekly basis. We used 
primarily human cells, which were stored in incubators at a constant 
temperature of 37oC with CO2 levels also kept constant at 5%. 
Depending upon the number of cells required for downstream use, cells 
were kept in T175, T75 or T25 sterile flasks in Dulbecco’s Modified 
Eagle Media (DMEM media) (Life Technologies)) with 10% Fetal Calf 
Serum (FCS) and 1% (v/v) penicillin/streptomycin (Life Technologies), 
with or without selection antibiotics. When cells reached confluency they 
	 83	
were split at 1/4 or 1/5 ratios. During cell splitting, the media was 
removed and the cells were washed in 1 x PBS. Cells were then 
detached from the flask surface using trypsin EDTA (1ml for a T75). 
Once cells were detached, the trypsin solution was neutralized by the 
addition of DMEM media. Cell suspensions were then distributed into 
new flasks or plated for use. All the above was conducted under a 
sterile fume hood in a specified tissue culture room. 
 
Cell pelleting and storage 
A standard protocol was used in each experiment to minimize error.  
The first step was to examine the flask/plate under a microscope to 
check for cell health and confluence. Once a clear layer of cells was 
apparent the cells were considered eligible for harvesting.  
The next step was to remove the FCS from the cells and wash them 
with 5mls of 1 % PBS solution.  For T75 flasks, once the PBS was 
removed, 1 ml of trypsin was added to each flask, which was then 
tapped until all cells became non-adherent. Finally, 5 mls of medium 
was added to the flask and the contents were siphoned into a 15 cm 
falcon tube (kept on ice) for centrifugation. Cells were centrifuged at 500 
rcf for 5 minutes and the supernatant was discarded. The cell pellet was 
then re-suspended in 1 % PBS and centrifuged for at 500 rcf for a 
further 5 minutes. All supernatant was completely discarded at this 





Formalin fixed, paraffin embedded human bladder cancer tissue was 
sectioned and wax-mounted on slides for storage. These were dewaxed 
using xylene washes x 2 for 10 minutes. The samples were then 
rehydrated using sequential washes in 100 %, then 95 % ethanol for 2-3 
minutes each. The slides were then incubated in an H202/Methanol (30 
ml H202 + 270 ml methanol) mix at room temperature for 20 minutes. 
This was washed using running tap water for 5 minutes. For antigen 
retrieval the slides were incubated in a slide rack in 0.01 M citrate, which 
was boiled in a microwave for 4 minutes and then allowed to cool on the 
bench for 10 minutes. Following this the slides were rinsed using PBST 
for 10 minutes before blocking with Avidin/biotin for 30 minutes 
immediately followed by a second block with 10 % goat serum for 
another 30 minutes.  
The primary antibody (diluted in 2% goat serum) and negative controls 
(1 x PBS with 2 % goat serum) were then added to the slides (1 ml per 
slide). This incubation was typically for 2 hours or overnight in the fridge 
(4-8oC). Following this the slides were washed in 1 x PBS for 2 x 5 
minutes. A secondary antibody was then added (goat anti-mouse 
biotinylated) at the desired dilution in 2 % goat serum for 1 hour at room 
temperature. Next a couple of drops of a premixed Avidin Biotin 
Complex ((ABC) Vecta Shield) was added to each slides followed by 3 x 
5 minute PBST washes. Following this a DAB mixture (Vecta Shield) 
with H202 and buffer was added to the slides for between 4 and 10 
minutes (the slides were observed for a brown colour saturation 
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signifying when the incubation was long enough) followed by another 
wash with running tap water for 5 minutes. Gills haematoxylin dye was 
added for 1 minute followed by a second wash in tap water. Finally the 
slides were re-dehydrated using incrementally more pure ethanol (70 %, 
90 %, 95 %, 100 %) to incubate the slides in for 3 minutes a time. The 
slides were then mounted after a brief submersion in Xylene with poly 
para-xylene (PPX). 
 
Fluorescence in situ hybridization (FISH) 
Typically 293T or HeLa cells were used in 24-well plates with coverslips. 
On the day of processing, the media was first aspirated and then the 
slides were washed with 1 x PBS three times. 150-200 µL of FISH fix 
solution (see miscellaneous buffers) was added to each well and left to 
incubate for 20-30 minutes under the fume hood. This was followed by 
three washes with 500 µL of 1 x PBS to remove the fix. The slides were 
then placed on 3 mm Whatmann filter paper and placed in a 60 mm 
Petri-dish. 100 µL of FISH hybridization buffer (see miscellaneous 
buffers) was added to each slide and left to incubate at 37oC for 2 
hours. This was followed by another three washes with 1 x PBS. The 
slides were then mounted using mounting glue (Vecta Shield) containing 
DAPI. This was sealed and left to dry overnight. Slides were stored at 
4oC.  
For immuno-staining, a similar process was followed, however, after the 
hybridization incubation the slides were incubated with 100 µL of a 
primary antibody diluted in 1 x PBS with 1 % BSA for 1 hour at room 
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temperature in the dark. A secondary antibody was added following 
three 1 x PBS washes for 30 minutes in the dark, also diluted in 1 x PBS 
with 1% BSA.  
 
 
Colony counting assays 
Plated cells were subjected to different levels or types of DNA damage 
one day after plating into a 6 well plate. Each well was subjected to DNA 
damage for a period of 7 days. At 7 days, the media was removed and a 
staining solution (crystal violet) was added (enough to cover base of 
well (typically 1 ml). This was left for 20 minutes at room temperature 
and then carefully removed using slowly running tap water washes. The 
plates were left to air dry and then counted by eye using a hand held 
cell counter.  
 
Nascent mRNA capture 
Control RNAi and PARG RNAi cells were plated in an ‘Ibidi’ 8 well dish 
and induced every 48 hours for 72 hours. Following this the cells were 
labeled using 1 mM 5-ethynyl uridine (diluted in 250 µl of DMEM + 10 % 
FCS media) incubation for 1 hour at 37oC. The media was then changed 
and the cells were subjected to 2 mM H202 and left to incubate for 0 to 8 
hours (0 time point cells were collected immediately following H202 
treatment). After the incubation with H202 the media was removed and 
cells were washed once in 1 x PBS and then fixed using the FISH fix 
solution for 15 minutes. The cells were then washed in 1 x PBS a further 
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time and permeabilised using an incubation of 250 µL of 0.5 % Triton X 
100 in 1 x PBS for 15 minutes at room temperature. Next 1 ml of Click-
iT reaction mixture was added to the cells and incubated for 30 minutes 
as per protocol (see Life Technologies). The cells were given a last 
wash using Click-iT rinse buffer and then mounted on slides. The slides 














Chapter 3: The role of tobacco 
smoke in bladder cancer 
 
Work in this chapter contributed to the publication of: 
 
Cumberbatch MG, Rota M, Catto JW, La Vecchia C. (2015) The Role of 
Tobacco Smoke in Bladder and Kidney Carcinogenesis: A 
Comparison of Exposures and Meta-analysis of Incidence and 
Mortality Risks. Eur Urol. Jul 3. pii: S0302-2838(15)00548-5 
 
Herein, I investigate part one of the contemporary landscape behind the 
epidemiology of bladder cancer (BC).  
 
 
3.1. SYSTEMATIC REVIEW AND META-ANALYSIS OF 
RISK OF BLADDER CANCER IN SMOKERS 
Tobacco smoke is the commonest cause of BC and includes a mix of 
carcinogens implicated in the aetiology of BC. In general, the WHO 
estimates that in 2013 there were more than 1 billion smokers worldwide 
(Islami et al., 2015) and around 6 million people die each year from 
tobacco related illnesses. The risks of tobacco related illnesses vary 
with the duration and intensity of smoking (Freedman et al., 2011; 
Samanic et al., 2006), together with the type of tobacco and mode of 
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administration (cigarettes versus pipe smoking or chewing), and an 
individual’s ability to detoxify (Samanic et al., 2006). What is less clear is 
whether smoking cessation reduces the risk of BC to baseline. 
Tobacco may be prepared through flue (blonde) and air curing (black). 
The latter contains a greater concentration of nitrosamines, biphenyls 
and arylamines and is hence thought to be more carcinogenic (Samanic 
et al., 2006; De Stefani et al., 1991; Momas et al., 1994). With regards 
to carcinogen detoxification, variations in the activity of NAT2 (N-acetyl-
transferase 2) and GSTM1 (Glutathione S-transferase Mu 1) due to 
polymorphism appear to affect cancer risk from smoking (Burger et al., 
2013). It is also evident that tobacco smoke can induce changes in the 
DNA damage response (DDR) machinery which can 
additively/synergistically impair the host response to carcinogens 
(Borzym-Kluczyk et al., 2009; Rouissi et al., 2011). I look more closely 
at the DDR in Chapter 6. 
 
I conducted a systematic review and meta-analysis of the literature to: 
better understand the contemporary relationship of tobacco smoking in 
the epidemiology of BC, to facilitate an understanding of the current 
most ‘at risk’ populations and to evaluate whether smoking cessation 
does reduce risk (and by what margin). 
 
3.2. DATA ACQUISITION 
I commenced this systematic review in August 2013 with myself as lead 
author and three other senior co-authors (full methods are explained in 
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Cumberbatch et al., 2015a). Briefly, the PubMed database was 
searched for all to-date original articles in English using the string terms 
‘tobacco’, ‘smoking’ AND ‘bladder cancer’. Articles were included in the 
meta-analysis if they met the following inclusion criteria: i) case-control, 
cohort or nested case-control studies published as original articles in 
English investigating the relationship between smoking and the risk of 
BC in humans ii) the outcome was incidence or disease-specific 
mortality (DSM) and iii) odds ratio (OR), hazard ratio (HR) or relative risk 
(RR) estimates with their 95% confidence intervals (CI), or enough 
information to calculate them, were reported. We excluded summary 
data (reviews) and reports not focusing on our research question or 
describing molecular effects in cell lines. We report our findings in 
accordance with the PRISMA guidelines (Moher et al, 2009). If multiple 
RRs or ORs were presented in the original articles, we extracted the 
estimates from the maximally adjusted model in order to reduce the risk 
of possible unmeasured confounding (Greenland, 1987). 
 
Because cancer is a relatively rare outcome, we assumed that ORs, risk 
ratios and rate ratios were all comparable estimates of the RR. To 
conduct the meta-analysis, measures of association and the 





3.3. CURRENT SMOKERS HAVE THE GREATEST BC 
RISK INCIDENCE AND MORTALITY 
We identified 2,683 papers, of which 83 studies investigating BC met 
the inclusion criteria. The pooled relative risk (PRR) of BC incidence in 
“all”-smokers was 2.53 (95% CI 2.37-2.80), in “current”-smokers was 
3.47  (3.13-3.88), and in “ex”-smokers was 2.04 (1.85-2.25). The pooled 
RR of BC disease specific mortality risk (DSM) was 1.47 (1.20-1.84), 
1.43 (1.24-1.75) and 1.44 (0.99-2.11) in “all”, “current” and “ex” 


















Figure 3.1.  Consort flow diagram demonstrating the search strategy for 











Figure 3.2. Pooled relative risks (RRs) and 95% confidence intervals 
(CIs) for incidence and mortality from Bladder Cancer in relation to 









 Incidence Mortality 
No. of 
comparisons† 
Pooled RR  
(95% CI) 




Pooled RR  
(95% CI) 
I2 % (p for 
heterogeneity) 





89.8 (<0.001) -- -- -- 
Cohort studies 37 2.17 
(1.89-2.48) 
82.7 (<0.001) 12 1.47 
(1.24-1.75) 
30.9 (<0.001) 
Overall 146 2.58 
(2.37-2.80) 
87.9 (<0.001) 12 1.47 
(1.24-1.75) 
30.9 (<0.001) 




(2.13-2.84) 89.1 (<0.001) 
0 -- -- 
Cohort studies 6 1.80 




Overall 53 2.38 









80.2 (<0.001) 0 -- -- 
Cohort studies 13 2.53 
(2.27-3.47) 
84.5 (<0.001) 5 1.45 
(1.12-2.09) 
42.0 (0.1) 
Overall 46 3.47 
(3.07-3.91) 
80.9 (<0.001) 5 1.45 
(1.12-2.09) 
42.0 (0.1) 





78.1 (<0.001) 0 -- -- 
Cohort studies 18 1.92 
(1.72-2.15) 
63.3 (<0.001) 4 1.44 
(0.99-2.11) 
53.1 (0.09) 
Overall 47 2.04 
(1.85-2.25) 
78.6 (<0.001) 4 1.44 
(0.99-2.11) 
53.1 (0.09) 




Figure 3.3. Pooled relative risks (RRs) and 95% confidence intervals 
(CIs) for incidence and mortality from bladder cancer in relation to ever 








 Incidence Mortality 
No. of 
comparisons† 
Pooled RR  
(95% CI) 




Pooled RR  
(95% CI) 
I2 % (p for 
heterogeneity) 
Gender† 
Male 42 2.56 
(2.17-3.01) 
92.1 (<0.001) 6 1.87 
(1.50-2.33) 
0.0 (0.9) 
Female 31 2.36 
(1.95-2.86) 
85.5 (<0.001) 3 1.59 
(1.02-2.32) 
0.0 (0.07) 
Mixed 73 2.68 
(2.40-2.99) 




Europe 59 3.09 
(2.71-3.53) 
79.9 (<0.001) 4 1.92 
(1.37-2.25) 
0.0 (0.6) 
Asia 16 2.16 
(1.72-2.71) 
82.3 (<0.001) 5 1.56 
(1.24-1.97) 
0.0 (0.9) 
Americas 62 2.39 
(2.12-2.70) 
92.3 (<0.001) 3 1.11 
(0.93-1.32) 
0.0 (0.9) 
Africa 8 1.99 
(1.25-3.15) 
88.4 (<0.001) 0 -- -- 
	 	 † Some studies may include separate estimates for males and females and/or for smoking category. 
‡ The sum does not add up to the total number of studies included in the meta-analysis since only studies reporting estimates separately for men 
and women were selected. 
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Figure 3.5. A Begg plot of BC incidence. Visual inspection of this plot 
shows that the spread of studies is symmetrical around the midline 










This review has shown that tobacco smoking still significantly increases 
incidence risk of BC. I have quantified these risks using the most up to 
date published literature. 
 
Incidence and DSM risk is greatest in current smokers and lowest in ex-
smokers, indicating that quitting confers benefit. However, the risk does 
not return to the baseline levels of non-smokers suggesting both a 
reversible and non-reversible harm from tobacco. There may be a 
permanent cellular change that occurs in the lining of the bladder that is 















Chapter 4: Occupational carcinogen 
exposure and bladder cancer 
 
Work in this chapter contributed to the publication of: 
 
Cumberbatch MG, Cox A, Teare D, and Catto JWF. (2015) Changing 
trends in occupational bladder cancer: A systematic review and 
meta-analysis.  JAMA Oncol. Dec 1;1(9):1282-90 
 
Herein, I investigate part two of the contemporary landscape behind the 
epidemiology of bladder cancer (BC).  
 
 
4.1. SYSTEMATIC REVIEW AND META-ANALYSIS OF 
RISK OF BLADDER CANCER BY OCCUPATIONAL 
CARCINOGEN EXPOSURE: BACKGROUND 
As discussed in Chapter 3, BC has two main aetiological risk factors. 
The second commonest exposure to carcinogens is through 
occupational tasks (Reulen et al.,	 2008). Such exposure can be direct 
(e.g. solvents from paint) or indirect (e.g. diesel exhaust in lorry drivers). 
Despite workplace hygiene reducing carcinogen exposure, many BCs 
still arise through occupational exposure. Most tumors arise following 
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exposure to exogenous carcinogens that enter the circulation through 
inhalation, ingestion or skin contact. This route has been known for 
many years and has been reduced through workplace health and safety 
regulations in most countries. Examples include European Union 
directives (e.g. 90/394/EEC and 98/24/EC) and the 2002 Control of 
Substances Hazardous to Health Regulations in the UK. More recently 
studies have focused on an interaction between tobacco products and 
genetic polymorphisms in detoxification enzymes (Pesch et al., 2013; 
Porru et al., 2014). This is a developing area with genome wide 
association studies (GWAS) becoming ever more important (Figueroa et 
al., 2016). 
 
In 1981 Doll and Peto estimated that 10% of BCs arose from 
occupational exposure (Doll and Peto, 1981). Given the 20-30 year 
latency between exposure and cancer, we felt that a renewed appraisal 
of the attributable risk of occupational BC was required, as we expected 
that workplace legislation has now reduced this rate. Indeed at first 
glance of contemporary literature, workplace legislation has changed 
the incidence of BC arising from occupational exposure to 5.3% of all 
BC, and 7.1% in males (Rushton et al., 2010). However, these 
attributable fraction estimates are derived from exposure prevalence 
and relative risks for recognized carcinogens. They exclude tumors 
where carcinogen exposure is unrecognised (occult) (Noon et al., 2012), 
unregulated or the agent is unknown. Evidence of uncontrolled 
occupational exposures can be derived from demographic data where 
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BC incidence mirrors industrial rather than smoking patterns. For 
example, the incidence of BC in the UK varies considerably between 
regions in a pattern not reflected by smoking difference. In 2011 data 
showed that the number of total BC cases in England was 11.1/100,000, 
whereas in Northern Ireland it was 8.6/100,000 (UK avg. 10.9). 
However, smoking incidence in England was 18.4/100,000 (the lowest 
in UK) compared with Scotland, which was 21.1/100,000 for (UK avg. 
18.7). Interestingly, regional industries differ considerably 
(http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Businesses+by+I
ndustry+Sector) (Cumberbatch et al., 2015b).  
 
So what agents are responsible? With regards carcinogenicity, chemical 
agents are classified according to the surety of cancer risk. To date, 
many definitive bladder carcinogens (International Agency for Research 
on Cancer (IARC) category 1) have been identified (Baan et al., 2009). 
The use of most high-risk bladder carcinogens is now controlled. 
Therefore contemporary occupational exposures are likely to be to lower 
risk chemicals with less clearly defined carcinogenic potential (IARC 2a 
(probable) or 2b (possible)) (Cumberbatch et al., 2015b). We 
hypothesized a change in occupational risk has occurred through social 
and workplace legislative changes, and that this has lead to a change in 
profile of occupations and workforces at risk of BC. To examine this 
hypothesis, we undertook a systematic review and meta-analyses of 
contemporary reports of occupational exposure and bladder 
carcinogenesis. We compared these to similar historical reports. 
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4.2. DATA ACQUISITION 
In May 2014 a final systematic search was performed using the 
PubMed, Medline, Embase and Web of Science databases. We 
included full-text articles published or in press, with no time or language 
limits applied. We used a variety of terms for occupation and either BC 
or urothelial/transitional cell carcinoma. Abstracts of all reports were 
read and full papers retrieved for those appearing to fulfill selection 
criteria. This was performed by two independent reviewers, myself and 
my supervisor, James Catto. Articles were eligible if they reported 
original data on occupational risk for BC in adults. Reports were case-
control or cohort studies by design, and were required to focus on 
occupational exposures as the main analysis, they needed to have 
sufficient data to calculate confidence intervals with no missing data. We 
selected the most recent and maximally adjusted data from populations 
with multiple reports to ensure contemporaneity and to minimize bias 
(from confounders such as tobacco smoking or socio-economic factors). 
Risk estimates were annotated by occupational class using NYK and 
ISCO-1958 codes (Pukkala et al., 2009) and dates of exposure (taken 
as the mid-time point of documented exposure interval). For meta-
analysis, we used manuscripts reporting risk estimates (e.g. odds ratio 
(OR), standardized incidence ratio (SIR), standardized mortality ratio 
(SMR) or relative risk (RR)) and 95% confidence intervals, or enough 
information to calculate these (Cumberbatch et al., 2015b). 
Meta-analysis of risks was performed using a random effects model 
using STATA (Vsn 12.0, StataCorp LP, TX). This model was chosen as 
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we anticipated heterogeneity between studies given the nature of 
occupational BC reports (e.g. few with large populations, most have low 
disease incidences, all are non-randomised and most are retrospective 
in design). We assessed heterogeneity (I2) between studies for each 
occupation. Incidence and disease specific mortality (DSM) risk were 
computed separately. Publication bias was evaluated by visual 
inspection of funnel plots, Egger’s linear regression (Egger et al., 1997) 








Figure 4.1. Consort diagram showing our search strategy of 

























4.3. THE FACE OF OCCUPATIONAL BC HAS CHANGED 
We identified 2,844 manuscripts, from which we read 697 full papers 
and selected 263 for systematic review (reporting 31.4 million persons). 
These manuscripts reported BC risk in 1,254 occupations, which were 
sub-classified into the NYK and ISCO-1958 codes for occupational 
class. Whilst funnel plots suggested symmetry for each comparison, 
statistical analyses identified potential publication bias for males and 
incidence data. One occupation (Racehorse Trainers/Jockeys) had a 
single report, whilst all other occupational classes had multiple 
estimations of risk (mean 27 (st. dev. 25) comparisons per occupation).  
 
Historically, occupations exposed to aromatic amines (rubber, dye, 
plastic, printing and hairdressing) were at greatest risk of BC. Gradually, 
restrictions on the use of many implicated carcinogens have been 
introduced. Some of these include 2-napthylamine in the rubber industry 
(sanctioned since 1949) (Zheng et al., 2002), di- and trichloroethane 
and MBOCA used as solvents in plastic manufacturing (Stula et al., 
1978; Dost et al., 2009), and carbon black in print inks (Lynge et al., 
2009).  
For meta-analysis of our review data, we used data from 231,627 cases 
and 4.76 million controls annotated in 217 manuscripts by occupation. 
The highest pooled incidence risk was for tobacco workers (RR 1.72 
[95%CI 1.37-2.15]) and dye workers (RR 13.4 {95%CI 1.5-48.2}) but the 
greatest RR in any study was for factory workers (RR 16.6 [95%CI 2.1-
131.3)]). Pooled DSM was greatest for metal workers (RR 10.2 [95%CI 
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6.89-15.09]) and gardeners (RR 5.5 [95%CI 0.84-35.89]) and the 































Figure 4.2. The pattern of BC incidence in males and females over the 















Figure 4.3. The pattern of BC mortality in males and females over the 











Figure 4.4. Forrest plot of BC incidence amongst all occupations 
 
NOTE: Weights are from random effects analysis
Overall  (I−squared = 98.2%, p = 0.000)
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Figure 4.5. Forrest plot of BC mortality amongst all occupations 
 
 
NOTE: Weights are from random effects analysis
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Despite improvements in workplace hygiene many occupations still 
have an elevated BC incidence and mortality risk. This highlights the 
public health importance of occupational BC. When we analysed 
whether the risk within each occupation had declined overtime, there 
was no clear difference except for drivers. Overall incidence 
experienced an expected dip during the 1980’s, however unexpectedly it 
appears to be on the rise again. Improved detection mechanisms or 
screening are possible reasons for this. This trend is most striking for 
women and this may reflect changes in the gender composition of the 
workplace and changes to social norms. 
 
There is seemingly still an exposure risk from aromatic amines and this 
group have the highest incidence, whilst those exposed to polycyclic 
aromatic hydrocarbons and heavy metals have the greatest mortality.  
Other agents attracting attention are diesel fumes and combustion by-
products (drivers and firefighters). 
 
In conclusion, the profile of contemporary occupations with increased 
BC risk is broad and differs for incidence and mortality and it may be 
some time before we see whether more recent restrictions have an 
impact. For the meantime, these meta-analyses have informed my 
knowledge of current at risk groups. This information has been useful to 
develop a protocol for a cohort study of our local population looking 
more specifically at the occupational carcinogens that high-risk industry 
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personnel are currently handling, and during which workplace tasks. In 
the future, we may be look to 
develop cell lines from patients known to have been exposed to 





















Chapter 5: LUZP4 functions as an 
alternative mRNA export adaptor in 
some cancer cells 
 
Work in this chapter contributed towards the publication of: 
 
Viphakone N, Cumberbatch MG, Livingstone MJ, Heath PR, Dickman 
MJ, Catto JW, Wilson SA.  (2015) Luzp4 defines a new mRNA export 
pathway in cancer cells. Nucleic Acids Res. Feb 27;43(4):2353-66 
 
Herein, we interrogate the role of the cancer testis antigen LUZP4 as a 
putative mRNA export adaptor. 
 
 
5.1. LUZP4 AND CANCER TESTIS ANTIGENS 
In the previous two chapters, I updated the literature on the aetiology of 
bladder cancer. Having identified that the two primary risk factors still 
persist in contemporary society, I accepted the challenge to investigate 
the basic science behind BC and cancer in general. My aim was to try 
and identify novel targets that might be used for diagnostics or 
therapeutics. 
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At the time of commencing this PhD there were some exciting 
preliminary findings in the Wilson laboratory and so I decided to focus 
my early efforts on a cancer testis antigen (CTA) known as LUZP4. 
 
In order for gene expression to be successful, all steps from 
transcription to translation must be complete. One of the more complex 
tasks is to license and export mRNA from the nucleus to the cytoplasm. 
A key complex involved in this step is TREX. The earliest component of 
the TREX complex to be recruited to nascently transcribed mRNA is the 
RNA helicase UAP56. A canonical binding partner for UAP56 is the 
mRNA export adaptor ALYREF. As mentioned in the introduction, in 
2011 the Wilson laboratory identified two proteins during a BLAST 
(basic local alignment search tool) search that contained the same 
peptide sequence as ALYREF at the UBM (UAP56 binding motif) 
domain [DMSLDDII]. Hautbergue et al (2011) published the first paper 
on UIF, one of these two proteins. They showed that UIF could function 
as an mRNA export adaptor and shared redundancy with ALYREF. UIF 
was able to complement the role of ALYREF when it was knocked down 
(Hautbergue et al., 2011) as is seen in some cancer cells. 
 
The second protein identified in this search was LUZP4. LUZP4 was a 
previously uncharacterized gene. Tureci et al (2002) wrote the first 
paper on LUZP4. They arrived at a few interesting conclusions: LUZP4 
seemed to co-localise to nuclear speckles alongside sites of 
transcriptional activity and splice sites; chromosomal mapping showed 
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that like most CTA’s the gene locus for LUZP4 is housed on the X-
chromosome; and it exclusively shared structural features with the N-
myc proto-oncogene. Whilst, Tureci et al (2002) were successful in 
recording the cellular localization of LUZP4 and showed by RT-qPCR 
that its levels are increased at the RNA level in some cancers, they did 
not attempt to identify binding partners of LUZP4 and interrogate its 
molecular function in detail.  
 
Investigating the role and function of LUZP4 represented the ideal 
project. Preliminary data suggested that LUZP4 would have a role both 
in mRNA export and, may be a suitable target for development as a 
biomarker for cancer or as a therapeutic target for vaccine therapies 
(Tureci et al. 2002) to treat cancer.  Such promise has been seen during 
investigations of CTAs in other cancers such as prostate (Shiaishi et al., 
2012) and pancreatic (Kubuschok et al., 2004). Finding a reliable 
biomarker (diagnostic or prognostic) is of particular importance to the 
Urologist and for the BC community. To date attempts to develop a 
















Figure 5.1. Schematic showing shared N terminal peptide sequence in 
ALYREF, UIF and LUZP4.  The UBM previously identified in ALYREF 
and UIF aligns with a homologous sequence in LUZP4. Red residues 







5.2. PRESENCE OF LUZP4 IN BLADDER CANCER 
The first task was to identify how widespread is the expression of 
LUZP4. The experiments were run in two arms. We first confirmed that 
ALYREF was down-regulated in MeWo melanoma cells by blotting 
expression of ALYREF in 293T (control) and MeWo (experimental) cell 
lines. Following on from the western blotting, we then sought to see 
whether or not the same patterns of expression seen at the protein level 
were shown at the mRNA level, through qRT-PCR. This time we also 
probed for the expression of LUZP4. Our antibody for LUZP4 was not 
capable of detecting the endogenous protein and so we used qRT-PCR 
to detect mRNA levels of expression. We used 7 BC cell lines were 
tested using the standard qRT-PCR protocol from the Wilson laboratory. 
We performed four biological replicates and averaged the data. These 
showed that in the 7 BC cell lines (and MeWo positive control), when 
ALYREF is down-regulated in the cancer cells, LUZP4 is up regulated. 
The housekeeping gene U1 was used as a normalizing control. We 
ranked the cell lines according to their described grade (level of 
differentiation) and metastatic status on harvesting from the donor on 
review of the literature using PubMed and cell-bank databases. Having 
established these rankings, we noticed that as the cancer cell lines 
became more ‘aggressive’ the pattern of ALYREF down regulation with 
simultaneous up regulation of LUZP4 became more evident (see 
Figures 5.2 and 5.3). We then repeated this experiment 4 times and all 









Figure 5.2. A western blotting showing that ALYREF is down-regulated 
in the MeWo (melanoma) and bladder cancer cell line RT112, whilst 
normally expressed in the 293T embryonic kidney cells. Tubulin was 
















Figure 5.3. qRT-PCR results (with error bars of standard deviation) 


















Figure 5.4. Conceptual diagram showing a simplified version of our 
hypothesis that cancer cells use of an alternative method of mRNA 









5.3. EXPRESSION OF LUZP4 ACROSS CANCER TYPES 
Following our previous line of investigation, we next wanted to illustrate 
whether or not the expression patterns seen in our BC qRT-PCR were 
also seen in cancer arising from other tissues. In order to complete this 
large-scale qRT-PCT experiment we purchased pre-prepared Tissue 
Scan 96-well plates from Origene. These are pre-made 96-well plates 
containing normalized cDNA for a large range of cancers. In total, 3 sets 
of 5 plates were used to evaluate 18 different body tissues, from adrenal 
gland to uterus. We adapted our qPCR protocol to be in accordance to 
the Origene protocol. Data was analyzed using the MX-Pro programme 
and Microsoft excel. The delta CT value was used to determine the 
relative abundance of each primer per each well condition.  
One primer was used per plate. Each 96 well plate was made up of 96 
different well contents but each well was exactly matched to an identical 
well on 2 other plates, allowing comparison. Three empty wells were 
provided, and these were used to evaluate a none-template control (in 
duplicate) for each primer. We did not probe for a housekeeping gene 
such as U1 because Origene guarantee an equal cDNA loading across 















Figure 5.5. qRT-PCR of commercially purchased (Origene) cDNA 
arrays from cancer tissues originating from 18 different organs. Data 
presented show the percentage of tumour cDNAs that expressed each 






These data successfully show that ALYREF is down-regulated in cancer 
cells, whilst the LUZP4 export adaptor pathway is seemingly up-
regulated (a hypothetical pathway is displayed in figure 5.4). 
Overwhelmingly, it is in skin that the greatest expression level resides 
(figure 5.5). We believe that this may be due to an active switch from 
one export pathway to another in cancer cells in order to promote 
survival. We have seen that cells become dependent on these 
alternative mRNA export pathways as when ALYREF and UIF are 
simultaneously subjected to RNAi the cells die rapidly (Hautbergue et 
al., 2011). As hypothesized, there also appears to be a functional 
overlap between ALYREF and LUZP4 in certain cancer cells. In vivo 
work by Viphakone et al. (2015) showed in a cell survival assay when 
melanoma cells are subject to LUZP4 RNAi (shown to express low 
levels of ALYREF) the cells die earlier than control cells suggesting a 
dependence on this alternative export pathway (synthetic lethality). 
 
In the data shown here, we have seen that the hypothesized 
relationship of these export adaptors within the cancer cells, appears 
not only restricted to one or two types of cancer, but appears to be a 
more widespread phenomenon.  
 
5.4. LUZP4 AS AN ONCOGENE 
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Karni et al (2007) found that the splicing factor SF2 was up-regulated in 
some cancers. They successfully showed that by injecting immune-
deficient mice with SF2 cells, malignant tumours developed above and 
beyond tumours seen in the control group. Taking inspiration from this 
we wanted to see if the presence of LUZP4 could promote de novo 
malignant tumour growth in immune-deficient mice. 5 x 106 cells were 
injected into the flanks of severe combined immune-deficient (SCID) 
mice of negative control (flag 3t3), positive control (SF2 3t3) and 
experimental (LUZP4 3t3) cells. Each condition had triplicate mice and 
equal distribution of gender was ensured. This experiment was 
conducted with full Home Office approval at Sheffield Medical School 
under the supervision of Professor Nicola Brown. 
 
Every 3 days the mice were inspected for tumour growth in the flanks 
and standardized calipers were used to measure growth. After 18 days 
the mice were culled according to Home Office regulations to avoid the 
morbidity of a large tumour burden. SF2 and LUZP4 injected mice 
began to grow palpable tumours after 5 days (figure 5.6). After 12 days 
tumours began to grow in the negative control mice, and these 
eventually became larger than in the LUZP4 mice. By 18 days it was 
clear that no difference existed between injecting 3t3 and LUZP4 3t3 
cells (figure 5.7).  
 
The tumour sections were excised and examined in two ways: 1) 
Haematoxylin and Eosin staining and pathologist-led microscopy to look 
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for malignant properties such as apoptotic bodies, invasion and chaotic 
mitosis. 2) Tumours were lysed and processed for total RNA extraction 
and qRT-PCR was performed to look for LUZP4 expression. We found 
that approximately 50% of the LUZP4 tumours were sarcomatous 
tumours and 50% were inflammatory only. LUZP4 was negligibly 
detectable at the RNA level and there was no difference across 
experimental conditions. These results led to the conclusion that LUZP4 


























Figure 5.6. Tumour identification and excision in SCID mice following 
injection of 3t3 cells. The delivery of cells, tumour monitoring and culling 
of mice was performed by Professor Nicola Brown’s laboratory. I 









Figure 5.7. Growth curve of tumours in SCID mice injected with 5 x106 
cells of 3t3, SF2 3t3 or LUZP4 3t3. The SF2 3t3 cells were used as a 










5.5. LUZP4 IMMUNOHISTOCHEMISTRY 
Attempts were also made to extract RNA from urine of 100 BC patients 
matched to patients without BC. Unfortunately, the yield of RNA from 
the stored samples was insufficient. I therefore decided to investigate 
whether LUZP4 could be detected using IHC on BC tissue and whether 
we could delineate BC from benign tissue based upon the presence of a 
LUZP4 signal (figure 5.8). Such a result would potentially allow the 
surgeon to stain a tissue intra-operatively and assess whether surgical 
resection margins had been adequate much like the use of fresh frozen 
sections, which are sent to the pathologist intra-operatively. Patient 
bladder tissue samples were prepared as per our immunohistochemistry 
protocol. Slides were probed for localization and abundance of 
ALYREF, LUZP4 and UIF. There was a general localization to the 
urothelium but there was no difference in this between conditions 
despite the use of a number of different antibody dilutions, purifications 











                                 
Figure 5.8. Immunohistochemistry slides of paraffin embedded bladder 
cancer sections incubated with ALYREF and LUZP4 antibodies. There 






5.6. EFFECTS OF DNA DAMAGE IN ALYREF RNAI CELL 
LINES 
We performed colony survival assays on ALYREF RNAi and Control 
RNAi cell lines. Cells were incubated in increasing doses of Cisplatin 
and Mitomycin C to see whether cells devoid of ALYREF are more 
susceptible to DNA damaging agents. This was done to examine the 
hypothesis of synthetic lethality across the mRNA export adaptors.  
Cisplatin and Mitomycin C are both chemotherapeutic agents currently 
in use for the treatment of BC (figure 5.9). Mitomycin C is typically used 
as an intravesical instillation treatment following identification of NMIBC 
and Cisplatin is usually reserved for systemic treatment in patients with 
locally advanced or metastatic MIBC.  
 
If preferential growth inhibition could be shown in cells with low ALYREF 
levels compared to cells with normal ALYREF, it might be that the 
inhibition being caused by the drug treatments is through action on the 
alterative mRNA export pathway of LUZP4-assisted mRNA export, 
normally redundant in control cells. This would pose an interesting 
therapeutic possibility. 
 
The results showed an apparent increased sensitivity to DNA damage in 
ALYREF RNAi cells. However, the results were not statistically 





          
 
Figure 5.9. Colony forming assays using crystal violet staining 
performed in Control RNAi and ALYREF RNAi cell lines using the 
chemotherapeutic agents as labeled. These experiments we performed 
in triplicate and averages are shown here. The number of colonies with 
each drug concentration was normalized to the number of colonies at 




In the publication by Viphakone et al (2015), LUZP4 is shown to function 
as a bona fide mRNA export adaptor. Using Co-IP and RNAi 
complementation assays (where a cell line co-expresses RNAi hairpins 
to ALYREF and an RNAi resistant LUZP4 cDNA) Viphakone et al (2015) 
show that LUZP4 can bind RNA, and TREX subunit UAP56, can bind 
the nuclear export receptor NXF1 and LUZP4 can complement the loss 
of ALYREF in MeWo cells rescuing cell survival. In that paper we show 
that LUZP4 can partially complement the survival of cells that have lost 
both ALYREF and UAP56 in a double knock down RNAi screen. This is 
a phenotype that is normally cell-lethal in 6 days. Furthermore, upon 
LUZP4 RNAi, malignant melanoma cells (MeWo) show a sensitivity 
beyond that of control RNAi cells. Given that the levels of ALYREF are 
low in these cells, these results suggest a functional crossover and 
redundancy of LUZP4 with ALYREF, which gives way to a synthetic 
lethality upon RNAi of LUZP4.  
 
My contribution to this work suggested LUZP4 is an mRNA export 
adaptor that has raised levels, at the protein and RNA level, in a large 
number of cancer cell lines where ALYREF levels are down, in 
particualar melanoma cells.  This raises the suspicion that there is a 
‘switch’ to LUZP4 governed mRNA export that occurs in certain cancer 
cells that have lost ALYREF. We found no evidence to support the idea 
that LUZP4 functions as an oncogene and we were unable to 
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demonstrate an increase expression of LUZP4 in BC patient urine or 
tissues, limiting the prospects of LUZP4 as a potential biomarker for BC. 
 
An interesting future direction would be to screen a library of small 
molecule inhibitors against UIF and LUZP4 to confirm that the loss of 
these pathways results in selective cancer cell death. 
 
An argument against this work would be to question the applicability 
and feasibility of providing a medical alternative to current therapies 
based on a small molecule screen. However, we have seen the 
possibilities with the advent of Curaxins – a group of small molecule 
inhibitors currently being put through the rigors of clinical trials courtesy 
of Cleveland Biolabs (Gasparian et al., 2011). This vastly improves the 
likely turn-around-time it would take to process another, similar, clinical 












Chapter 6: Effect of DNA damage 
and subsequent poly (ADP-
ribosyl)ation on mRNA export  
 
In this chapter I examine the relationship between DNA damage and 
mRNA export. Specifically, I wanted to test whether DNA damage 
induced poly (ADP-ribosyl)ation leads to alterations in the mRNA export 
pathway that culminate in an mRNA export block. 
 
6.1. POLY (ADP-RIBOSYL)ATION 
Poly (ADP-ribosyl)ation is one of many post-translational modifications. 
Upon such modifications, target proteins may undergo a change in their 
function or activity (see Introduction). Jungmichel et al. (2013) explain 
that poly (ADP-ribosyl)ation is a phenomena most frequently observed 
under conditions of genotoxic stress. This conclusion arose from the 
observation that PARP levels were increased when cells were subjected 
to treatments with DNA damaging agents such as H202 and UV 
radiation. The novel findings from Jungmichel et al. (2013) were that the 
effect is largely targeted towards proteins involved in RNA processing 
(Jungmichel et al., 2013). 
Strikingly, we noted that a common modification site for PARylation was 
the UAP56-binding motif (UBM) on ALYREF that we had previously 
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identified was essential for multiple TREX subunit interactions with 
UAP56 and thus TREX assembly (figure 6.1). Therefore this led to the 
hypothesis that PARylation of the UBM within TREX subunits might 
regulate TREX assembly, thus modulating mRNA export in times of 
DNA damage. What we did not know was whether TREX would still 
function and whether mRNA would still be correctly exported. We 
considered that there may be an mRNA export block following genotoxic 
stress, since export of transcripts derived from damaged DNA would be 


















Figure 6.1. Schematic of TREX: asterisks denote subunits known to 


















































6.2. PARG RNAi 
One of the first ways in which we wanted interrogate this hypothesis 
was to see what happened to TREX interactions and mRNA export 
under conditions of DNA damage. Since PARylation is a transient, 
reversible modification with a short half life (Li et al., 2014; Alvarez-
Gonzalez and Althaus, 1989) we generated a FLPIn 293 cell line with a 
stably integrated inducible miRNA which targets the major PAR 
glycohydrolase (PARG), allowing stable tetracycline (Tet) inducible 
knockdown of PARG, to reduce turnover of PAR and facilitate studies 
on the role of PARylation in mRNA export. 
The RNAi method exploits the functions of miRNAs (microRNAs). They 
are short non-coding RNAs that degrade or suppress gene expression 
of complementary mRNA.  Using the Block-iT kit (Invitrogen) we utilised 
this system to create stable inducible miRNA hairpins from a pcDNA 6.2 
GW vector against our target mRNA.  The engineered pre-miRNA 
hairpins are cloned into the Pol II miR RNAi expression vector. Once 
cloned in, these hairpin loop-structures are expressed by the 
mammalian cells and are cleaved into approximately 22 base-pairs (bp) 
transcripts by the enzyme Dicer. The single stranded siRNA is then 
incorporated into an RNA-induced silencing complex (RISC). This 
complex then targets the complementary mRNA and carries out specific 
cleavage or translational repression (depending on whether this 
complementarity is complete or not). 
To construct the PARG RNAi cell line we followed the ‘Block it’ kit 
protocol. We synthesized three hairpins for PARG RNAi using this 
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system. We then transiently transfected these hairpins (HPs) into 293T 
cells and performed a western blot that was probed with a 1/2000 
dilution of a PARG antibody (Millipore) to look for knockdown of co-
transfected PARG using tubulin as a loading control (1/10,000, Sigma). 
Our western blot showed that the best knockdown was with a combined 
transient transfection with hairpins 2 and 3 (figure 6.2). This inspired us 
to chain these hairpins together (as per the Block iT protocol) and create 
























Figure 6.2. Knockdown of myc-tagged PARG in 293T cells co-
transfected with myc tagged PARG and PARG RNAi hairpins (HP). Co-
transfection with hairpins 2 and 3 gave the greatest knockdown. Tubulin 















            
 
Figure 6.3. Western analysis of the FlpIn 293 cell line with a stably 
integrated inducible miRNA targeting PARG. Tetracycline (1 µg/ µL) was 






















Figure 6.4. Generated by Polly Gravells of Dr Helen Bryant’s laboratory. 
Our PARG RNAi cell line was aliquoted and shared with Dr Bryant’s 
laboratory. This figure shows that the PARG RNAi stable cell line 
knocks down PARG and not PARP. Jungmichel S et al (2013) showed 
that it is the isoform PARP1, not PARP 2 that is responsible for the 






6.3. THERE IS A TOTAL mRNA EXPORT BLOCK UPON 
INDUCTION OF PARG RNAi IN CONDITIONS OF DNA 
DAMAGE 
Jungmichel et al (2013) showed that a large proportion of PARylation 
protein targets are involved in RNA processing. From the supplementary 
data of a similar paper (Zhang et al., 2013) we found a number of the 
TREX subunits (20% of all targets). We hypothesized, that poly (ADP-
ribosyl)ation of said targets might result in a mRNA export block. To 
interrogate this hypothesis we decided to first test whether there was an 
effect on global mRNA export when PARylation was induced using H202 
oxidative stress. To conduct this experiment we used the Click-iT 
nascent mRNA capture kit (Life Technologies) (Figure 6.5). 
The click-iT kit allows the labeling or nascently transcribed RNA with a 
fluorescent signal. In a control background, following this labeling, the 
RNA cytoplasmic signal diminished rapidly and was largely absent by 4 
hours. This is because the mRNA is exported into the cytoplasm and 
turned over. The cytoplasmic RNA signal in 293 cells is very difficult to 
observe, even using other methods such as oligo(dT) FISH.  In contrast, 
in PARG RNAi cells subjected to H202 treatment, the nascent RNA 
remained nuclear throughout the 8 hour time course and this was 
reversed when PARylation was blocked using a PARP inhibitor 
(Nu1025, Enzo) (Figure 6.6). In the absence of a DNA damaging agent, 
cells with PARG knocked down, also showed some accumulation of 
nascent RNA in the nucleus, presumably due to PARylation triggered by 
spontaneous DNA damage. The accumulation of nascent RNA in cells 
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following DNA damage was similar to that observed when TREX was 
disabled by the combined knockdown of THOC5 and ALYREF (figure. 
6.6, right column). These experiments cannot formally exclude the 
possibility that the nuclear accumulation of nascent RNA arises because 
of a defect in RNA processing which would also trigger an mRNA export 
block. However, most splicing occurs co-transcriptionally and is rapidly 
proceeded by cleavage/polyadenylation of mRNAs. Moreover, the 
nascent RNA was labeled for 1 hour prior to any DNA damage; 
therefore many of the labeled transcripts are likely to be fully processed. 
Therefore the results suggest that upon H202 treatment there is an 
effect, caused by PARylation, which reduces mRNA export and this is in 















Figure 6.5. Schematic of the Click-iT experiment [Adapted from 
Buck SB et al. BioTechniques 2008] 1) Pulse-chase ethynyl uridine (EU) 
labeling 2) Click iT technology explained. There is a free alkyne group 
on the EU label incorporated into the RNA at uridine sites 
(approximately every 35th (LifeTechnologies)), this is then bound by an 
azide group on the Alexa fluorophore forming a triazole bound in a 









Figure 6.6. Click-iT pulse-chase EU labeling experiments. EU 












6.4. COIMMUNOPRECIPITATION PATTERNS OF ALYREF 
WITH UAP56 UNDER DNA DAMAGE STRESS 
Following on from our observations during our nascent mRNA export 
assay, we looked back at the library of proteins shown by Jungmichel et 
al. (2013) and confirmed that ALYREF is a known target. Jungmichel et 
al. (2013) also mapped the residues of the proteins that are known to be 
PARylated and an overwhelming majority for ALYREF resided within the 
two UBM regions (see Figure 6.8).  We decided to examine whether 
DNA damage with H202 treatment would show a PARylation effect on 
ALYREF binding to UAP56, as this partnership is crucial for appropriate 
TREX assembly (Dufu et al., 2010). 
We performed our standard co-immunoprecipitation (Co-IP) experiment 
with initially 4 experimental conditions. We pre-incubated protein 
sepharose G beads with either ALYREF or Influenza Hemagglutinin 
(HA) as per protocol. For our DNA damage condition we exposed a 
15cm dish of control or PARG RNAi cells with 200 µM H202 for 1 hour 
with or without a pre-incubation with 10 µM NU1025 PARP inhibitor. We 
then lysed the cells using a standard IP lysis buffer. For those lysates 
that were destined to be incubated on the ALYREF bound beads, we 
lysed in the presence of 1 µM of PARG inhibitor (Enzo) to further sustain 
the poly (ADP-ribosyl)ation modification. We saw that PARylated high 
molecular weight proteins were detected in the ALYREF IP, when 
subjected to a H202 shock (Figure 6.8, top left panel).  This result 
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validates the mass spectrometry data and suggests that TREX subunits 
which will CO-IP with ALYREF are PARylated in response to DNA 
damage.  We also noticed that there was a modest increase in the 
amount of UAP56 which CO-IPed with ALYREF in conditions of DNA 
damage when PARylation persisted due to PARG RNAi (figure 6.7, left 
hand side, bottom panels). To investigate this further we repeated the 
Co-IP experiments with ALYREF in stringent conditions using 1M NaCl 
in the binding and wash buffers (figure 6.7, right panels). In these 
conditions it was clear that DNA damage induced PARylation led to 
stabilisation of the UAP56:ALYREF complex particularly following PARG 
knockdown. Moreover, this effect was seen with two different DNA 
damage conditions (MMS and H2O2) and could be reversed by PARP 
inhibitor, confirming the effect was dependent upon PARylation.  
There is an enrichment of the Co-IP of these two TREX subunits under 
DNA damage conditions, which is amplified in the more stringent 
conditions of high salt. Appropriate levels of DNA damage are confirmed 
by the detected of multiple PARylated proteins by probing with the anti-









Figure 6.7: Co-Immunoprecipitation (Co-IP) of ALYREF and UAP56 
under conditions of DNA damage using H202 and the alkylating agent 
MMS (methyl methane sulphonate). 
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6.5. IDENTIFYING THE PAR BINDING SITE ON UAP56 
Ultimately, we wanted to design a set of experiments where we induced 
DNA damage and examined the interactions of TREX subunits (in 
particular ALYREF and UAP56) in conditions with and without PAR 
binding to UAP56 in order to assess the specific effects of poly (ADP-
ribosyl)ation on the ability of these two proteins to bind one another and 
for them to carry out their normal function. For example, we wanted to 
determine whether the effects of PARylation would prevent UAP56 from 
performing its helicase and ATPase activity. 
As mentioned briefly above, mass spectrometry based proteome 
wide studies of PARylation targets identified numerous RNA binding 
protein targets. Zhang Y et al (2013) showed that 20 % of the 
PARylated proteins mapped involved TREX subunits (Zhang et al., 
2013). Within this dataset, it was striking that a common modification 
site for PARylation was the UBM (UAP56-binding motif) of TREX 
subunits ALYREF and CHTOP, previously shown to be essential for 
their assembly (Chang et al., 2013) (figure 6.8). Whilst it had been 
shown by previous authors (Jungmichel et al., 2013; Zhang et al., 2013) 
that ALYREF was a target of PARylation, it had not been clearly shown 
that UAP56 could be PARylated. Gagne et al (2008), performed an in-
silico analysis of PAR-binding proteins and showed that they seem to 
share a consensus peptide sequence, KDFQRRIL (Gagne et al., 2008). 
This was hence thought to be a putative binding domain for PAR. 
Strikingly, this sequence resides within the C terminal half of UAP56 










Figure 6.8. Schematic of ADP ribosylation sites on ALYREF and 
















Figure 6.9. Crystal structure of Uap56 with the proposed PAR-binding 











We designed an experiment to test whether UAP56 could bind PAR in–
vitro using biotinylated PAR incubated on streptavidin beads, and tested 
whether His-tagged pet24b-UAP56 would pulldown with PAR in rabbit 
reticulocyte lysate (figure 6.10). We found that full length UAP56 bound 
PAR, and furthermore discovered that the N- and the C-terminal 




























Figure 6.10. Pulldown of pet24b-UAP56 and UAP56 truncations in 








Having identified that UAP56 could bind PAR, we decided to test 
whether mutations in the putative PAR-binding site would prevent 
binding of UAP56 to PAR in vitro. We designed a range of mutations 
within the peptide sequence KDFQRRIL using our site-directed 
mutagenesis protocol, and our most impressive outcomes were from 
mutations to the juxtaposing phenylalanine and glutamate (figure 6.10, 
6.11), changing them to alanines (KDAARRIL). Mutating phenylalanine 
and glutamate to alanines on putative PAR-binding site on UAP56 
reduces binding to PAR. This experiment was conducted with and 
without RNase A added to the wash buffers to ensure that binding was 





















Figure 6.11. Pulldown of pet24b-UAP56 and UAP56 binding site PAR 










Next we wanted to assess whether the ALYREF UBM could still bind the 
UAP56-PAR binding site mutant. Our results show that the ALYREF 
UBM binds less efficiently when the putative PAR-binding site is double 
mutated. This experiment was conducted with and without RNase A 
(images with RNAse A shown) added to the wash buffers to ensure that 
binding was direct and not bridged by RNA (figure 6.12 and 6.13). That 
the UBM does not pull down with the UAP56 mutant, which does not 
bind PAR suggests that the UBM and PAR binding sites are one and the 
same on UAP56. This finding suggests that the normal ALYREF 
UBM:UAP56 interaction is replaced with an ALYREF-PAR:UAP56 
interaction ie. PAR replaces the UBM in making the interaction between 
ALYREF and UAP56. Contrary to this, the full length ALYREF can still 
bind the UAP56 mutant. This can be explained by earlier published work 
(Golovanov et al., 2006) because the ALYREF RRM (RNA recognition 
motif) outside of the UBM also makes contact with UAP56. Furthermore, 
the protein CIP29 can also bind the Uap56 mutants confirming that the 
non-binding of the UAP56-PAR binding site mutants to the ALYREF 
UBM is not due to the UAP56 mutants being unable to bind anything 












Figure 6.12. GST-ALYREF WT UBM (N terminal) pulldown with PAR-
binding site mutations and full length WT UAP56-pet24b in reticulocyte 














Figure 6.13. Pulldown with GST-tagged full length WT ALYREF 
protein and UAP56 with putative PAR-binding site mutations. GST and 













Figure 6.14. Pulldown using UAP56-pet24b in reticulocyte lysate with 
GST-tagged purified proteins. RNase A was added to the wash buffers 
to ensure that binding was direct and not bridged by RNA. Coomassie 






Having identified the PAR-binding site on UAP56 we wanted to see 
whether we could show, in vivo, that PARylation of UAP56 is indeed 
responsible for the mRNA export block that we have observed 
previously upon DNA damage and whether this may be because of an 
alteration in the activity of UAP56. By mutating the UAP56-PAR binding 
site, there might be an alteration in the ability of UAP56 to conduct its 
helicase and ATPase activities in vivo. We had the idea that we could 
use at least one of these biochemistry experiments along with mRNA 
export assays to examine this. We created a complementation cell line 
(Viphakone et al., 2012) whereby we inserted an RNAi resistant WT 
UAP56 cDNA into an FRT vector containing UAP56 and DDX39 RNAi 
hairpins. We also made the same cell line using our most potent mutant 
of the UAP56-PAR binding site. By constructing these cell lines we were 
hopeful that we could see whether PARylation of UAP56 and the 
associated mRNA export defects could be negated by the expression of 
a UAP56-PAR binding site mutant. The rationale being that if one has a 
mutant of UAP56 which no longer binds PAR well but can still bind 
UAP56, then we should be able to dissect the importance of ALYREF 







6.6. IS LOCALISATION OF COMMON EXPORT FACTORS 
ALTERED UPON DNA DAMAGE? 
Subsequent to our findings above, that global mRNA export is down-
regulated upon H202 induced DNA damage, we wanted to find out what 
cellular localization changes are occurring that might reflect/be 
responsible for this blockade. In addition to interrogating the interactome 
between core TREX components under stress conditions (above), we 
sought to determine whether or not TREX components have altered 
cellular localization upon DNA damage. 
Reed and Hurt (2002) showed that subunits of TREX complex are 
distributed throughout the nucleoplasm, and largely reside in nuclear 
speckles (Reed and Hurt, 2002). This has been shown by TREX subunit 
co-localisation with splicing factor SC35. Viphakone et al (2015) showed 
that LUZP4 (see Chapter 5) had a distinctly different nuclear localization 
when it’s UBM was deleted (truncated mutant). Given the changes to 
the binding of the ALYREF UBM to UAP56 when PARylated secondary 
to DNA damage, we wondered whether we would see a novel nuclear 
localization phenotype upon treatment with H202. 
 
To investigate this, immunostaining (see materials and methods) 
of 293T cells was used. Cells were either probed with antibodies for 
endogenous proteins or were transfected with GFP-tagged TREX 
subunit proteins. The cells were co-stained for SC35, a protein known to 
localize to nuclear speckles. Cells were also stained for DAPI to 
highlight the nucleus (as it binds to DNA). All pictures were taken at the 
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same exposure level. Where indicated cells were treated with Triton-X 
pre-fixation and/or Actinomycin D was added for 2 hours pre-staining 
where indicated, to reduce the nascent RNA signal. This was performed 
so that any difference in localization would not be due to inadvertent 
perturbation of transcription (see figures 6.15 to 6.17). For ALYREF, 
UAP56 and CHTOP we saw no substantial changes in cellular 


























Figure 6.15. Immunofluorescence on 293T cells to assess the cellular 
localization of ALYREF upon under normal conditions and DNA damage 















Figure 6.16. Immunofluorescence on 293T cells to assess the cellular 
localization of UAP56 upon under normal conditions and DNA damage 















Figure 6.17. Immunofluorescence on 293T cells to assess the cellular 
localization of CHTOP upon under normal conditions and DNA damage 









Finally, we know that the Wilson laboratory has previously shown how 
NXF1 associates to the nuclear envelope and that this phenotype is lost 
when core TREX subunits ALYREF and THOC2 are depleted by RNAi 
(Viphakone et al., 2012). Here we wanted to investigate whether the 
same defect was apparent upon treatment with H202. This was 
especially interesting given that NXF1 and its co-factor NXT1 are targets 
of poly (ADP-ribosyl)ation as reported by Jungmichel et al. (2011) 
(figure 6.1). There were no substantial changes in association with the 
nuclear envelope for either NXF1 or NXT1 upon DNA damage (figures 
6.18 and 6.19).  It is accepted that a limitation of immune-fluorescence 



















Figure 6.18. Immunofluorescence on 293T cells to assess the cellular 
localization of NXF1 upon under normal conditions and DNA damage 
















Figure 6.19. Immunofluorescence on 293T cells to assess the cellular 
localization of P15 (NXT1) upon under normal conditions and DNA 




6.7. LIVE mRNA IMAGING: CLONING OF SPINACH2 AND 
mCHERRY INTO pCI NEO VECTOR 
Following on from my Click-iT experiments as a mode of examining 
mRNA export patterns, I decided that it would be useful to build and 
utilize a system of live mRNA capture. Work by Strack and Jaffrey et al 
(2013) showed how a novel RNA imaging modality known as Spinach-2 
could be used to perform such a task (see introduction) (Strack et al., 
2013). We used a pCI Neo vector expressing the RFP mCherry as the 
destination for cloning in multiple copies of the Spinach2 sequence. It 
was not known how many repeats of the Spinach2 would be needed to 
adequately image the live capture of mRNA in our chosen vector. In 
order to maximize our chances of detection we designed 
oligonucleotides to permit concatermization of the Spinach2 gene 
sequence (below). Using the generated overhangs, we used XhoI and 
SalI restriction enzymes to perform repeated restriction digests of 
Spinach2 sequence. In total I created a 9’mer aptamer of the sequence. 
5’ GAAATGGTGAAGGACGGGTCCAGTAGGCTGCTTCGGCAGCCT 
ACTTGT 3’ 
Following the construction of 3’, 6’ and 9’ copy aptamers, I transfected 
Cos-7 cells alongside a GFP control and two aptameric constructs from 
the Jaffrey laboratory (CGG and 5S). Unfortunately, despite the 9-copy 
aptameric construct, I was unable to see a convincing green 
luminescence from Spinach2 despite detecting an acceptable amount of 







Figure 6.20. Microscope captured live-images of Spinach 2 transfected 











During this arm of my thesis, I interrogated the effects of DNA damage 
on TREX assembly and mRNA export. Through Click-iT nascent mRNA 
capture I have identified that a global mRNA export block ensues 
following treatment with H202, and that this is more pronounced following 
PARG RNAi suggesting a role of poly (ADP-ribosyl)ation. Following on 
from this I have demonstrated an effect on TREX assembly following 
MMS and H202 treatments. The interaction between the RNA helicase 
UAP56 and mRNA export adaptor ALYREF appears altered upon DNA 
damage, this too seems to be related to the PTM of poly(ADP-
ribosyl)ation.  Furthermore, I identified the PAR binding site on UAP56 
and have shown that mutations in a consensus peptide sequence found 
in UAP56 and other PARylation targets do reduce the pulldown 
efficiency of UAP56 and biotinylated-PAR. Mutations in this sequence 
also affect the ability (in vitro) of the ALYREF N-terminal UBM to 
pulldown with UAP56. 
An exciting future avenue would be to look at the functional significance 
of DNA damage induced PARylation of ALYREF and UAP56 on the 
ability of UAP56 to exert its ATPase or helicase roles. Work to this end 
is underway in the Wilson laboratory. 
Lastly, in an attempt to study the effects of DNA damage on mRNA 
export using a live imaging technique, Spinach2, we were unable to 
reliably detect a fluorescence signal applicable for this aim. Since this 
work was completed, the Jaffrey lab have created a new construct 
known as Broccoli which is much improved, however, the integration of 
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Broccoli into this thesis was not possible within the time constraints 

























CHAPTER 7: DISCUSSION 
 
7.1. THE ROLE OF TOBACCO SMOKING AND 
OCCUPATIONAL CARCINOGEN EXPOSURE IN BLADDER 
CARCINOGENESIS: TWO META-ANALYSES 
Bladder cancer is an intriguing research area with a high financial 
burden and high morbidity and mortality. It is among the commonest 
smoking-related cancers and has a clear relationship to occupational 
and lifestyle carcinogenic exposures. What makes the bladder 
susceptible to exogenous carcinogens is the way in which it acts as a 
reservoir for urine that may contain carcinogenic metabolites, and 
infrequent micturition (a risk factor for BC (Cumberbatch et al., 2015a; 
Cumberbatch et al., 2015b) may lead to prolonged exposure from these 
by the urothelial lining of the bladder. Current tobacco smoking still 
confers the greatest incidence and disease-specific mortality BC risk. 
 
BC has historically been more common in men than women, but studies 
from the last two decades suggest that this trend has reversed. This 
would seem to reflect societal changes in the workplace and also 
lifestyle modifications.  
In recent years we have started to understand the molecular basis of 
this cancer and these have largely arisen from a better understanding of 
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the aforementioned primary aetiologies (pointing to the importance of 
chapters 3 and 4).  
Tobacco contains a rich source of polycyclic aromatic hydrocarbons, 
aromatic amines and N-nitroso compounds that cause DNA damage 
through bulky adduct formations, DNA breaks and base modifications 
(Stern et al., 2009). These tobacco carcinogens are detoxified by N-
acetyltransferases and glutathione-S-transferases. It has been shown 
that individuals with slow NAT2 acetylation status clear these 
metabolites less efficiently and as such may be predisposed to BC. 
Genome-wide studies are further interrogating the link between other 
polymorphisms and BC (Figueroa et al., 2016). 
It has been controversial whether quitting smoking actually confers a 
benefit to BC incidence but work in Chapter 3 suggests this is indeed 
the case. Another area of limited study is the role of second hand 
smoking (SHS), but our review suggests that there is an increased BC 
incidence from SHS (data not shown). It is hopeful that continuing 
tighter regulations on tobacco smoking will hopefully lead to reducing 
incidence rates in decades to come.   
 
With regards occupational BC, despite workplace hygiene 
improvements and industrial sanctions, people are still at risk of 
occupational carcinogen exposures linked to BC. In this thesis I show 
that there is a disparity between occupations with high incidences and 
those with high mortalities. It is within the occupations with 
disproportionately high mortality that the greatest interventional efforts 
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are required as we move forward, and research in this field may be best 
directed towards the individual tasks that are performed by individuals in 
these groups to try and identify crucial processes that put people at risk 
and reveal occult or poorly controlled carcinogens. Interestingly, we see 
that it is in women that the risk is greatest at present and this must 
clearly reflect a change in working patterns. Efforts to identify 
carcinogens in workplaces more heavily populated by women must be 
made. 
 
I can be confident in concluding that work within this thesis contributes 
towards the largest yet meta-analyses on the associations between 
smoking and occupational carcinogen exposure and bladder cancer. 
 
7.2. LUZP4 
Cancer testis antigens (CTAs) have been the focus of much scientific 
intrigue. There are currently more than 250 that have been 
characterized and the list is growing (Maxfield et al., 2015). As 
discussed earlier in this work, CTAs represent genes that are normally 
expressed in the testes, but may be aberrantly expressed in cancers 
derived from somatic cells. The testes are necessarily immune-
privileged as normal spermatogenesis generates auto-antigens that can 
elicited immune responses. Therefore, antigens provoked from 
anomalously expressed CTAs can evoke cellular or humoral immune 
responses (Maxfield et al., 2015; Zhong et al., 2015). Therefore they 
offer a novel utility in being able to illicit immune responses to cancer.  
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Potentially, therapeutically, CTAs may be introduced a means of 
immunotherapy. Indeed, early vaccinations using CTAs have been met 
with some success (Robbins et al., 2011; Wurz et al., 2016). 
 
Work from this thesis has provided data for the characterization of a 
previously poorly understood CTA, LUZP4. Our lab has shown that 
LUZP4 functions as an mRNA export adaptor, adopting many of the 
cellular mRNA export functions of the canonical TREX subunit ALYREF. 
LUZP4 has been shown to bind RNA at two domains (Viphakone et al., 
2015), it can Co-IP with many TREX subunits, requires a functional 
UBM for normal cellular localization, and is able to complement the loss 
of ALYREF in vivo.  It seems apparent that in some cancers (melanoma 
is the most convincing), the normally redundant LUZP4 mRNA export 
pathway is active and is integral to the gene expression. Our paper on 
LUZP4 has shown a convincing link between mRNA export and cancer. 
Beyond the realm of this project but nonetheless an interesting 
proposition, would be the creation of a small molecule inhibitor of 
LUZP4 for use in a mouse model of malignant melanomas. 
 
7.3. DNA DAMAGE 
In this thesis, I interrogate the link between DNA damage and mRNA 
export. I have shown that the oxidative stress imposed by H202 causes a 
global mRNA block in 293T cells. This block has been shown to be 
resultant from a PARylation effect. We can be convinced of this as the 
RNAi of PARG emphasizes this block, and the pre-incubation of cells 
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with a PARP inhibitor prevents this export block. Upon the same 
conditions, there is an enhance Co-IP of two core TREX components 
ALYREF and UAP56 (this is also true when cells are exposed to the 
alkylating agent MMS). Having observed an mRNA export block with 
oxidative stress, we would have hypothesized that there might be a mal-
assembly of these TREX subunits. The reason for the enhanced Co-IP 
is not clear. It may be hypothesized that either, under duress, TREX is 
stabilized as a means of promoting the processing and export of key 
transcripts for the cell to rescue function, or that perhaps this alteration 
in TREX assembly is a symptom of impending malfunction of the cell 
and is in fact a disabling interaction (figure 7.1). 
 
For the first time, I have shown that UAP56 can bind PAR in vitro. As 
proposed by Gagne et al. (2008), this PAR-binding site seems to be 
represented by the peptide sequence KDFQRRIL, found in the C 
terminus of UAP56. Mutations in this sequence prevent normal binding 
of PAR to UAP56. Furthermore, mutations in this site perturb binding of 
UAP56 to the ALYREF N-terminal UBM but not the full-length protein. 
This result, along with a pulldown of UAP56 truncations, suggests that 
the binding of PAR is at both the N and C termini. What remains to be 
concluded is the functional relevance of PAR binding to UAP56. It may 
be that UAP56 is no longer able to perform its RNA helicase or ATPase 
activity. Both of these functions are necessary to recruit TREX to 
nascent RNA and drive its assembly. Therefore, I have set about the 
purification of these proteins and devised an ATPase activity protocol 
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(modified from Chan et al. (1986)) where we can assess the ATPase 
activity of UAP56 with PAR-binding site mutations alongside WT UAP56 
and ALYREF. Alone, UAP56 has a weak ability to hydrolyse ATP but in 
the presence of ALYREF and/or RNA this is markedly increased (Chang 
et al., 2013). My hypothesis would be that the ATPase activity of the 
UAP56 mutant would be impaired following the mutation.  I also plan to 
supplement the reactions with free-PAR (Trevigen) to see whether this 
stimulates or hinders the ATPase activity of UAP56. 
 
Additionally, I have created a complementation cell line, wherein a 
cDNA of WT UAP56 resistant to RNAi has been incorporated into an 
FRT vector expressing hairpins for UAP56/DDX39 (UAP56 prologue) 
knockdown (figure 7.2). Concurrently, I have made the same cell line 
with a cDNA of the PAR-binding site double mutant also resistant to 
RNAi. We know from earlier work (Hautbergue et al., 2009) that 
UAP56/DDx39 RNAi is cell lethal in 6 days, and we know that there is 
an mRNA export block after 72 hours. The proposed experimental 
method with this cell line is to see whether the rescue of the mRNA 
export block expected with the WT RNAi resistant UAP56 is lost with the 
PAR-mutant.   
 
These experiments are designed but due to time constraints at the end 
of this project, they may have to be completed at a later stage. In 
summary my work on DNA damage has shown that PARylation plays a 
role in mRNA export, which has the potential to modulate which mRNAs 
	 178	
are exported and thus which proteins are expressed during this cellular 
stress.  
 
7.4. FUTURE DIRECTIONS 
I would like study whether certain DNA damage repair transcripts are 
still exported under these H202 induced PARylation conditions. In order 
to study this, one could design single-transcript FISH probes and 
perform FISH under conditions of DNA damage to see whether there is 
preferential export of these transcripts. Identifying which transcripts to 




















Figure 7.1. Proposed model showing that PAR can bind UAP56 and that 
under conditions of DNA damage, the TREX subunits ALYREF and UAP56 

















Figure 7.2. A pictorial description of the generation of a 
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